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LIST OF ABBREVIATIONS 
Term Abbreviation 
°C degrees Celsius 
µg microgram 
µM micromolar 
Aβ amyloid β 
AICD APP intracellular domain 
AD Alzheimer’s Disease 
APP amyloid precursor protein 
APPs APP soluble 
ApoE Apolipoprotein E 
B2M β-2 microglobulin 
BF1 brain factor 1 (gene: FOXG1) 
BM basal medium 
BMP bone morphogenic protein 
BDNF brain-derived neurotrophic factor 
BSA bovine serum albumin 
Ca2+ calcium ion 
cDNA complementary DNA 
Cl clone 
CTF carboxy-terminal fragment 
Cyclo Cyclopamine 
D day 
(db)cAMP N6,2′-O-Dibutyryladenosine 3′,5′-cyclic monophosphate 
sodium salt (dibutyryl cyclic AMP) 
DM dorsomorphin dihydrochlorate 
DMSO dimethyl sulfoxide 
DPBS Dulbecco’s phosphate buffered saline 
E6 Essential 6 
E8 Essential 8 
FA formaldehyde 
fAD familial AD 
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Term Abbreviation 
FCS fetal calf serum 
FGF fibroblast growth factor 
FOXG1 forkhead box protein G1 
FTD frontotemporal dementia 
GABA γ-aminobutyric acid 
GAD1 (GAD67) glutamate decarboxylase 1 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GDNF glial-derived neurotrophic factor 
GWAS genome-wide association studies 
hiPSC human induced pluripotent stem cell 
hPSC human pluripotent stem cell 
LDL low density lipoprotein 
LDN LDN 193189 
Ig immunoglobulin 
LMX1A LIM homebox transcription factor 1α 
LN521 laminin-521 
MAP2 microtubule-associated protein 2 
MAPT microtubule-associated protein tau 
MCI mild cognitive impairment 
MEA multi electrode array 
MEF mouse embryonic fibroblasts 
Mg2+ magnesium ion 
min minutes 
mL milliliter 
MM maturation medium 
mM millimolar 
Na-azide sodium azide 
NANOG homebox protein NANOG 
NFT neurofibrillary tangle 
ng nanogram 
nM nanomolar 
NPC neural progenitor 
OCT4 (POU5F1) octamer binding protein 4 
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Term Abbreviation 
OSKM OCT4, SOX2, Klf4, c-Myc, reprogramming factors to derive 
hiPSCs 
OTX2 homebox protein OTX2 
PAX6 paired box protein Pax-6 
PD PD0325901 
Pen/Strep Penicillin/Streptomycin 
PLO poly-L-ornithine 
POU5F1 (OCT4) POU-domain class 5 transcription factor 1 
PSC pluripotent stem cell 
PSEN Presenilin 
qPCR quantitative polymerase chain reaction 
RPL13 ribosomal protein L13 
rh recombinant human 
SATB2 special AT-rich sequence-binding protein 2 
SD standard deviation 
sec seconds 
SEM standard error of mean 
SLC17A6 (vGLUT2) gene name of vGLUT2 
SLC32A1 (vGAT1) gene name of vGAT1 
SOX1 transcription factor SOX1 
SOX2 transcription factor SOX2 
SOX10 transcription factor SOX10 
TBR1 T-box brain protein 1 
TBR2 T-box brain protein 2 
UBC poly-ubiquitin-C 
vGAT1 (SLC32A1) vesicular GABA transporter 
vGLUT2 vesicular glutamate transporter 2 
w with 
WNT Wingless int-1 
w/o without 
w/v weight per volume 
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Here, we focus on Alzheimer’s Disease, a neurodegenerative disease with an impact 
on the cortex, which is by far the most known of tauopathies, diseases that involve 
pathology around the tau protein. 
1.1.1 Alzheimer’s Disease  
In 2015 AD affected already 24 million people worldwide with a tendency to increase 
2-fold every 20 years (Mayeux & Stern 2012). Alzheimer’s Disease is with 60-70% the 
most frequent cause of dementia in patients (WHO, 2019). It comes along with several 
symptoms which show declined cognitive functions, such as reduction in thinking, 
feeling, behaving and perception, leading to impaired judging and finally to fully 
established dementia (Alzforum, 2018). 
Alzheimer’s Disease was discovered and defined by the psychiatrist Alois Alzheimer 
in 1906 and published in the monograph “Eine seltsame Erkrankung der Hirnrinde” in 
1907 (Alzheimer, 1907). He observed symptoms like rapid memory loss, disorientation 
in familiar places and hallucinations in his patient Auguste Deter, who was at the age 
of 51 when the first symptoms appeared in 1906. After her death by the age of 56, 
Alois Alzheimer examined her brain and found degeneration of the brain and the 
deposition of Aβ-plaques. When performing silver staining on brain slices, he could 
identify neurofibrillary tangles (NFTs) inside of neurons as well as remaining tangles 
after neuron death (Alzheimer, 1907). These neurofibrillary tangles consist mainly of 
tau proteins, as nowadays known (Kosik et al., 1986). Alois Alzheimer has observed 
such symptoms already before in other patients. As these patients were already at the 
age of 70 or older, he did not pay attention as he considered these symptoms as age-
 
Figure 2: Estimated prevalence of dementia from 2015 until 2050. 
Due to the older growing world population it is estimated that dementia cases will rise as well. In 2015 
approximately 50 million people suffered from dementia, it is expected that the number will rise up to 130 million 
cases in 2050. Figure from (Drew and Ashour, 2018). 
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related until he discovered the symptoms in Auguste Deter. These observations 
already pointed to the fact that AD can be divided into early-onset familial AD (fAD), 
which is being inherited in a genetic manner, and to late-onset sporadic AD, which 
appears in aged individuals. 
Phenotypic hallmarks of AD are the extracellular Aβ-plaques, also called amyloid-β 
plaques, and NFTs (Figure 3).  
Amyloid is a term for a protein-polysaccharide complex which is prone for forming 
fibrillary structures with β-sheet structure. Amyloid β, as the name already implicates, 
is also considered as an amyloid protein. Aβ-plaques mainly consist of aggregated Aβ 
proteins, which are either formed in a too high amount or consist of a too high ratio of 
a more aggregation-prone variant. Usually, neurons in the brain process the amyloid 
precursor protein (APP) by proteolytic cleavage into Aβ40, typically a 40 amino acid 
long fragment and to a lesser extent the more aggregation prone Aβ42 (roughly 10% 
of Aβ40) (Janelidze et al., 2016). In AD, a higher amount of Aβ42 compared to Aβ40 
is formed, which is more prone to form aggregates and deposits in the brain. Certain 
genetic fAD-causing mutations appear in the proteins that are involved in the 
proteolytic processing of APP (Alzforum, 2018). 
NFTs are usually intracellular helical deposits which mainly consist of the microtubule-
associated protein tau (Kosik et al., 1986). Tau is a protein that normally binds to 
 
Figure 3: Two molecular hallmarks of AD are amyloid plaques and neurofibrillary tangles. 
Comparison of a normal brain (left) and a brain affected by Alzheimer’s Disease (right). When the brain is 
affected by the disease, extracellular amyloid plaques form as well as intracellular neurofibrillary tangles. 
Neurons are stressed and will degenerate. Figure from (BrightFocusFoundation, 2017). 
Comparison of a normal brain (left) and a brain affected by Alzheimer’s Disease (right). When the brain is 
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microtubules in the axons of neurons and leads to their assembly and stabilization 
(Iqbal et al., 2005). Tau processing and microtubule dynamics, that is affected by tau, 
are very balanced processes that lead to a constant turnover of microtubules and 
proteins. This fine-tuned behavior seems to be in disbalance in disease. Due to 
enhanced post-translational modifications, mostly hyperphosphorylations, tau is 
detaching from microtubules, which are being destabilized, and they lose integrity 
(Alonso et al., 1994). Hyperphosphorylated tau is able to capture physiological tau and 
forms NFTs, making the physiological tau unavailable for microtubules (Alonso et al., 
1994). It is believed that microtubules degrade and the affected neurons degenerate. 
Caused by enhanced neuronal cell death, brain mass shrinks compared to brains of 
healthy individuals which is even visible at a gross pathology level in later stages of 
the disease (Figure 4). 
Development of brain pathology can also be described by different subsequent stages, 
so called Braak stages (Braak and Braak, 1991): Braak and Braak investigated post 
mortem brains of healthy individuals and patients with AD symptoms. They could find 
a timely expansion of Aβ-plaques and NFTs in the brain (Figure 5A and B). Braak and 
Braak divided the staging for Aβ-plaque distribution into 3 successive stages, called 
stage A, B and C (Figure 5A). Braak staging of NFT pathology was divided into 6 
successive Braak stages, namely I to VI. These stages are further characterized as 
 
Figure 4: Brain atrophy is observed in brains affected by AD compared to brains of healthy 
individuals. 
Schematic cross section of a healthy brain hemisphere (left) and one affected by Alzheimer’s Disease (right). 
The affected brain shows degeneration as the brain decreases. Figure from (Alzheimer's_Association, 2019). 
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the transentorhinal stage (stages I and II), the limbic stage (stages III and IV) and the 
 
Figure 6: Development of AD pathology over time. 
A: Braak staging of Aβ-plaques (Braak and Braak, 1991). Three stages were identified, called A, B and C. 
Shading marks occurrence of Aβ-plaques. 
B: Braak staging of NFT formation. 6 stages (Braak and Braak, 1991). were identified: Stage I/II is called 
transentorhinal stage, stage III/IV is called limbic stage and stage V/VI is called isocortical stage. Shading 
marks occurrence of NFTs. 
C: Development of pathology severity over time (Jack et al., 2010). First, Aβ pathology starts and develops to 
its fullest. Soon after, tau pathology follows. 
MCI: mild cognitive impairment.  
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isocortical stage (stages V and VI), according to their distribution pattern (Figure 5B). 
How Aβ-plaques and tau pathology spread in the brain, is not yet clear. However, it is 
hypothesized that distribution of pathology is similar to prion-like behavior (Jucker and 
Walker, 2013). 
Interestingly, Aβ-plaque progression does not correlate with any AD symptoms but 
starts sometimes decades before first symptoms of AD are detected. Therefore, Aβ-
plaque pathology is a very early indicator or biomarker for AD (Arriagada et al., 1992). 
Mild cognitive impairment (MCI) is diagnosed in patients with AD at later stages of 
disease pathology (Figure 5C). During this time point, Aβ pathology is already fully 
developed and tau pathology has strongly progressed. With increasing staging, 
symptoms worsen, leading to dementia (Figure 5C). 
 
Diseases which show neurofibrillary tangle formation are named tauopathies and AD 
is by far the most prominent, known and prevalent tauopathy (Goedert and Jakes, 
2005). Unlike for other tauopathies, in which mutations are found in the MAPT gene, 
this is not the case in AD although tau plays a crucial role in the pathogenesis of AD 
(Alzforum, 2018). Nevertheless, in AD molecular mechanisms of the disease and the 
interaction between plaques and NFTs still remain to be elucidated. 
Nowadays, genetic risk factors for AD are known as well as mutations leading to fAD. 
1.1.2 Genetic risk factors and mutations involved in AD  
In several genome-wide association studies (GWAS) for AD, the Apolipoprotein E 
(ApoE) locus was determined as risk factor for both sporadic and familial AD (Bertram 
et al., 2010). ApoE is a protein that is responsible for the transport of lipids and other 
proteins and binds to low density lipoprotein (LDL) receptors. 
Three major isoforms of ApoE exist: ApoE2, ApoE3 and ApoE4. The normal variant of 
ApoE is ApoE3, which is also the most common variant in the population (Raber et al., 
2004). Risk factor for AD is the isoform ApoE4 (Corder et al., 1993). Carrying one allele 
increases the likelihood to develop AD by approximately 4-fold, two alleles up to 13-
fold. Further, the ApoE4 allele leads to an earlier onset of disease in a dose-dependent 
manner (Raber et al., 2004). ApoE2 is much less common, the function is also not fully 
understood, but it seems to reduce the risk for developing AD while increasing the risk 
for developing a cardiovascular disease (Serrano-Pozo et al., 2011). Further, it was 
found out that ApoE4 is able to influence Aβ (Huang et al., 2017; Lin et al., 2018). 
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Mainly mutations that affect the amyloid precursor protein (APP) or components of its 
processing pathway, such as mutations in Presenilin (PSEN) 1 or 2 are found in fAD. 
APP, which is a membrane-spanning protein in neurons, is being processed in the 
amyloidogenic pathway by a β-secretase, which releases APPsβ-protein into the 
extracellular matrix (Figure 6). Subsequently, the γ-secretase, which is a catalytic 
protease complex, is cleaving the APP further, releasing Aβ into the extracellular space 
(Figure 6). The catalytic subunits of the γ-secretase are encoded by PSEN1 and 2 
(Kimberly et al., 2000).  
An all-embracing overview of all discovered mutations for fAD so far can be found on 
https://www.alzforum.org/mutations.  
Although NFTs can be found in brains of AD patients, no mutations in the MAPT gene 
were found in AD but are associated with closely related tauopathies such as 
frontotemporal dementia (FTD). Therefore, it is of great interest to understand the 
molecular mechanisms of AD pathology and the involvement of NFTs, as well as what 
discriminates the different tauopathies in their disease pathology.  
 
 
Figure 8: The amyloidogenic processing pathway of the amyloid precursor protein. 
The amyloid precursor protein (APP), which is a transmembrane protein in neurons, is cleaved by the 
β-secretase, which releases the APPsβ-part into the extracellular matrix. Subsequently, the γ-secretase is 
cleaving a further part of APP into Aβ into the extracellular matrix. APP: amyloid precursor protein, β: 
β secretase, γ: γ-secretase, APPs: APP soluble, CTF: carboxy-terminal fragment, AICD: APP intracellular 
domain. Figure adapted from (Haass et al., 2012). 
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Another important aspect in AD is neuroinflammation: the immune system in the brain 
becomes activated and may lead to damage in the brain. Alternatively, a dysfunctional 
immune system could fail in the normal cleaning and renewing processes in the brain, 
as well. In this regard, mutations in microglia, the resident immune cells of the brain, 
which are similar to macrophages, were identified that play a role in AD, such as 
mutations in TREM2 and CD33 (Alzforum, 2018; Bertram et al., 2010; Sirkis et al., 
2016). These mutations seem to be associated with a reduced microglia function and 
an increased risk of developing AD. 
Processes in pathology however remain not completely understood, especially in their 
interplay, or what process and pathology starts earlier and what are subsequent events 
that build on each other. Here, novel models for better understanding disease at an 
earlier stage can be of great advantage. 
1.1.3 Drugs used in AD cannot influence the disease, but they can ameliorate 
symptoms 
Only two types of drugs for AD and other tauopathies were brought to market until now: 
the two drug classes are acetylcholine esterase inhibitors and antagonists of NMDA-
type glutamate receptor (Orr et al., 2017). However, these treatments do not cure AD 
and other tauopathies, they rather ameliorate some cognitive symptoms and bring 
benefits for only a few months. 
Drug discovery efforts could not lead to new treatment paradigms in the last 16 years. 
Although various AD mouse models exist, they cannot reflect all parts of AD pathology. 
In AD animal models a lot of treatment approaches work to diminish Aβ-plaques and 
improve cognition, nevertheless translatability to humans is not working well (Franco 
and Cedazo-Minguez, 2014). 
Therefore, other disease models which are more authentic are necessary. One 
approach is the use of patient-specific human induced pluripotent stem cells (hiPSCs) 
(Sterneckert et al., 2014). By the help of this technology, neuronal cell types affected 
in AD, for instance cortical neurons, could be generated and disease modeling could 
be performed with a cell culture model that could not be closer related to the patient. 
Further, the hiPSC-technology could be used for drug discovery and drug screening 
approaches, therefore, it will be highlighted in more detail. 
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1.2 Pluripotent stem cells: a new promise for drug discovery 
In 1998 Thomson and his lab were able to isolate embryonic stem cells from human 
embryos and culture them in vitro (Thomson et al., 1998). It was possible to expand 
these cells indefinitely and in theory, these cells bear the potential to be able to 
differentiate into any cell type of the human body. With this success, hopes arised that 
these human embryonic stem cells (hESCs) could be used for developmental studies, 
as well as for drug discovery and regenerative medicine. 
Unfortunately, the use of hESCs comes along with ethical concerns as the ESCs bear 
the potential to create a human being when implanted into a blastocyst and more 
importantly, a human embryo is typically destroyed in the process of deriving these 
stem cells (Lo and Parham, 2009). Therefore, research on and with hESCs is not 
allowed in all countries and also tightly regulated in those that allow their use (Lo and 
Parham, 2009). 
Contrary accounts for induced pluripotent stem cells: these can be derived by 
reprogramming of somatic (fully matured) cells from the body of any individual 
(Takahashi et al., 2007). The simple overexpression of a set of few (typically four – 
OCT4, SOX2, KLF4, c-MYC) pluripotency – associated transcription factors is enough 
to “reprogram” a mature cell into a pluripotent state. These cells are fully pluripotent 
and can not only be eternally propagated, but also differentiated into all three germ 
layers (Takahashi et al., 2007). When first published by Yamanaka and colleagues, it 
 
Figure 10: The cycle of hiPSC-technology. 
Adapted figure from (Grskovic et al., 2011). iPSCs are being generated from a patient and differentiated into 
the cell type affected by disease. This system can be used for a “Disease in a dish” approach to study disease 
and find drug targets. Subsequently, cells can be used for a drug screening approach and drugs can be 
developed that help the patient in the disease. 
iPSCs: induced pluripotent stem cells 
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was quickly regarded as a promising alternative source of embryonic stem cells. This 
is also highlighted by the fact that Professor Yamanaka was awarded the Nobel Prize 
for Medicine and Physiology already in 2012, only five years after the discovery. When 
derived from patients with a specific disease, such as AD, these cells are a great tool 
to derive patient-specific cells suitable for disease modeling. Such a cellular system 
can further be used for drug discovery in later stages, such as drug screening and drug 
development (Figure 7). The hiPSC-technology was already successfully used for 
disease modeling of a wide range of diseases, including, among others, cardiac, 
neurological and neurodegenerative diseases such as Huntington’s or Parkinson’s 
Disease (Ebert et al., 2009; Ho et al., 2016; Moretti et al., 2010; Reinhardt et al., 2013; 
Ren et al., 2015). Also for AD, such cell culture systems were already used for disease 
modeling and even drug screening approaches (Brownjohn et al., 2017; Choi et al., 
2014; Duan et al., 2014; Huang et al., 2017; Kondo et al., 2013; Kondo et al., 2017; 
Woodruff et al., 2016).  
Therefore, with the growing need of adequate cell culture systems for drug discovery, 
the hiPSC technology bears a new promise for drug discovery in the future. 
1.3 Cell culture conditions of PSCs and the importance of xeno-free and 
chemically-defined culture conditions 
In 1959 Russel and Burch invented the “3R-concept”: It postulates that the use of 
animals and products derived out of them in research should be reduced, replaced and 
refined (reprinted in 1992 (Russel and Burch, 1992)). In the case of cell culture, 
especially also in PSC culture, a lot of animal-derived ingredients are used, for instance 
in cell culture media, or coating proteins and growth factors. 
In this attempt, it is an elegant idea to replace animal-derived factors by recombinant 
proteins of the same species of the culture to derive a xeno-free (free of foreign 
species) culture. 
 
When Thomson isolated human embryonic stem cells from blastocysts in 1998, he and 
his colleagues grew the cells on a feeder layer which were irradiated mouse embryonic 
fibroblasts (MEFs) in fetal calf serum (FCS)- components containing medium 
(Thomson et al., 1998). In his paper he mentioned that when growing ES cells in the 
absence of MEFs, the ES cells started to differentiate, indicating the importance of 
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MEFs in maintaining the pluripotency of hESCs, but it was unknown which trophic 
factors the MEFs provide. 
Nevertheless, the growth of hESCs on MEFs and in the conditioned media the MEFs 
produce, the cell culture system was very variable and not well defined. Development 
away from feeder layers and conditioned medium towards Matrigel (which is purified 
extracellular matrix) coating and more defined cell culture media gained in importance 
(Xu et al., 2001). In the next years, members of the Thomson lab started to optimize 
ESC culture medium and developed the chemically defined “TeSR” medium which 
allowed the culturing of hESCs in a feeder-free way (Ludwig et al., 2006). Further 
optimization finally led to the identification of the only eight absolutely necessary 
components of PSC-medium and the medium, called Essential 8 (E8) medium, is since 
then the state of the art for culturing both hESCs and hiPSCs under fully defined 
conditions (Chen et al., 2011). 
Other components from animal origin used in many, even more defined cell culture 
systems are Matrigel and bovine serum albumin (BSA), which can be found in cell 
culture media as well as a carrier protein in soluble protein preparations.
 
1.3.1 Matrigel 
When culturing hiPSCs and derived neural precursors and neurons, Matrigel is one of 
the major coating agents used. Matrigel is an extracellular matrix extracted from 
Engelbreth-Holm-Swarm mouse sarcoma. For this purpose, the tumor needs to be 
propagated in mice (Kibbey, 1994). As an extract, it may contain growth factors and 
extracellular proteins, which may vary from batch to batch and interfere when growing 
hiPSCs: Cells might spontaneously start differentiating.  
Xeno-free alternatives for Matrigel coating are recombinant proteins of the extracellular 
matrix, such as vitronectins, collagens, fibronectins and laminins, some of which are 
used when culturing hPSCs (Chen et al., 2011; Lam and Longaker, 2012; Yasuda et 
al., 2018). It was found that hiPSCs produce α-laminins to build their extracellular 
matrix for attachment but not the other proteins (Laperle et al., 2015). When knock-out 
cells were cultivated, they could survive using coating of recombinant laminin-521 
(Laperle et al., 2015). 
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1.3.2 Bovine serum albumin 
Another factor, that is ubiquitously used in cell culture media or supplements is bovine 
serum albumin (BSA). BSA is the main protein component of bovine serum and it bears 
several beneficial effects in vivo and for in vitro cell culture: It acts as an antioxidant, it 
binds several components such as various molecules, fatty acids, hormones, ect. That 
is the reason, why BSA was still kept as a medium component when serum was 
removed from cell culture conditions.  
Besides the mentioned use, BSA can act as a carrier protein when preparing soluble 
protein solutions to block unspecific binding sites for proteins in cell culture ware. 
When working with human cell culture, BSA can be replaced by human serum albumin 
(HSA) to derive a xeno-free cell culture condition. Unfortunately, HSA, which is 
extracted from blood donations, is more expensive. 
BSA is also component of the B27 supplement, which is widely used in media when 
culturing neurons or differentiating PSCs towards neurons to replace serum. 
Fortunately, a xeno-free B27 supplement consists which uses HSA instead. Further, 
B27 supplement might either include traces of vitamin A or may be free of vitamin A. 
Both supplements are being used in case of neural induction, although it was shown 
by Li and colleagues, that it might have an adverse effect on neural induction (Espuny-
Camacho et al., 2013; Kirkeby et al., 2012; Kirwan et al., 2015; Li et al., 2009; Shi et 
al., 2012a; Shi et al., 2012b). 
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1.4 Deriving cortical neurons from hiPSCs 
Pluripotent stem cells have the potential to theoretically differentiate into any cell type 
of interest. In the case of AD and other tauopathies, the affected cell types are cortical 
neurons. In this regard, it is of interest to derive cortical neurons from hiPSCs. A way 
to derive the right cell type is to differentiate hiPSCs towards the desired cell type by 
mimicking differentiation in vivo and to transfer findings into in vitro (Figure 8) (Mertens 
et al. 2016). Findings in vivo usually derived from experiments performed in Xenopus, 
chick embryos, mice or other species. It is thought that early development is a 
conserved process among a variety of species and therefore, most findings should be 
applicable also to human. Nevertheless, not all details could already be clarified in 
humans. An advantage of hESCs and hiPSCs is that unknown facts of development 
can also be analysed in this system. Therefore, some findings are also attributed to 
the use of hPSCs. 
 
During gastrulation in Xenopus, it was found out that a part of the ectoderm forms the 
neuroectoderm. This happens as some signaling molecules from underlaying 
organizer regions influence the formation of neuroectoderm by secreting components 
that influence pathways. In this regard, the bone morphogenic protein (BMP) inhibitor 
Noggin was identified: It is secreted by the Spemann organizer and leads to formation 
of neuroectoderm together with other signaling clues (Lamb et al., 1993). BMP activity 
induces epidermis formation in that part of ectoderm which does not form 
neuroectoderm (Wilson and Hemmati-Brivanlou, 1995). In later stages other secreted 
 
 
Figure 12: Recapitulation of neural development stages in vitro from structures found in vivo 
Figure from (Mertens et al., 2016). hPSCs: human pluripotent stem cells, ICM: inner cell mass. 
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proteins were identified, which were for instance follistatin, an antagonist of Activin 
signaling in the TGF-β pathway (Hemmati-Brivanlou and Melton, 1994). 
 
Various differentiation protocols from PSCs towards cortical neurons exist, but all 
protocols differ in some small details. In general, such differentiation protocols were 
divided into three different phases: 
 
1) neural induction 
2) expansion  
3) final maturation  
During neural induction, hiPSCs are forced out of the pluripotency state into the 
direction of the neuroectoderm to obtain neuroepithelial cells, which represent neural 
progenitors. During expansion, neural progenitors are expanded to generate a larger 
pool of cells and the neural progenitor cell (NPC) type is being manifested. The final 
maturation should lead to a final differentiation of NPCs into functional neurons. 
 
Two major signaling pathways are important for maintaining a pluripotent stem cell 
state in hiPSCs: FGF (typically basic FGF, also known as FGF2) signaling, which 
signals through the MAPK/MEK pathway, and TGF/Activin signaling, which signals 
through the SMAD2/3 pathway. These are also the only growth factors needed in the 
abovementioned E8 medium (Chen et al., 2011; Greber et al., 2011; Vallier et al., 
2005). 
 
Different approaches exist for neural induction of hPSCs: they can be grown as 
aggregates forming embryoid bodies or as adherent culture.  
When the embryoid body approach was used, it was found that no extrinsic signals 
were needed when aiming for neuroectoderm formation and postulated to be the 
default pathway when no other clues are used (Zhang et al., 2001). Nevertheless, this 
strategy greatly depends on “clean” media components and no unwanted tendencies 
of the PSCs to more efficiently differentiate into other than the neuroectodermal 
lineages. At later stages, inhibitors of BMP or TGF-β were applied which derived from 
findings of Xenopus described above (Elkabetz et al., 2008; Smith et al., 2008) The 
key for neural induction in an adherent system was to apply the so called double SMAD 
inhibition (dSMADi) which included the inhibition of both BMP and TGF-β pathways by 
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SB431542 and Noggin/Dorsomorphin which inhibit ALK4/5/7 (Activin/Nodal/TGF-β 
receptors) and ALK2/3/6 (BMP type I receptors) respectively, which signal through 
SMAD proteins (Figure 9) (Chambers et al., 2009). Inhibition of the TGF-β pathway 
antagonizes the pluripotency state of hiPSCs and prevents formation of mesendoderm, 
while the inhibition of the BMP pathway prevents formation of the trophectoderm and 
the non-neural ectoderm (Chambers et al., 2009; D'Amour et al., 2005; Tchieu et al., 
2017; Xu et al., 2002). Thus, dSMADi seems to be beneficial for neuroectoderm 
formation.  
 
Most protocols which followed still involved dSMADi, but addressed further pathways 
to enhance the induction towards dorsal forebrain, such as the WNT or MEK pathways 
(Greber et al., 2011; Moya et al., 2014; Qi et al., 2017; Shi et al., 2012a; Shi et al., 
2012b). 
WNT signaling is known to be involved on one hand in anterior-posterior patterning 
(Kirkeby et al., 2012; Moya et al., 2014), on the other hand in dorso-ventral patterning 
together with the antagonizing SHH signaling, which is responsible for ventral 
development (Li et al., 2009; Maroof et al., 2013). Further, it was found that 
WNT signaling might also contribute to neural crest formation (Chambers et al., 2012; 
Mica et al., 2013; Tchieu et al., 2017): neural crest progenitors form neurons of the 
peripheral nervous system and other cell types from the periphery.  
Further, it was described that WNT signaling is a factor of variability among hPSC lines 
(Blauwkamp et al., 2012; Moya et al., 2014; Ortmann and Vallier, 2017): it might be 
differentially activated in various PSC lines, but also change dynamically over time. 
 
Figure 14: Scheme of neuronal differentiation using dSMADi 
Figure adapted from (Chambers et al., 2009). Inhibition of TGF-β and BMP pathways leads to CNS formation 
and avoids formation of trophoectoderm, mesendoderm and endoderm. 
β
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The differential activity of WNT might contribute to different differentiation potentials or 
propensities (Blauwkamp et al., 2012; Moya et al., 2014; Ortmann and Vallier, 2017). 
Therefore, WNT inhibition might be beneficial for avoiding neural crest formation.  
Nevertheless, the differentiation from hiPSCs towards mature and functional neurons 
is a lengthy process needing up to several months to derive functional neurons (Kirwan 
et al., 2015). 
 
The role of FGF2 during neural induction has been quite controversial: Some groups 
claim its activation is necessary for neural induction (LaVaute et al., 2009), others 
describe more advantageous effects when FGF signaling is inhibited (Greber et al., 
2011; Yao et al., 2006). 
A way to accelerate neural induction and thus neuronal differentiation was described 
by Greber and colleagues (Greber et al., 2011): He described that when inhibiting 
MEK1/2, a downstream signaling pathway of FGF2, neural induction could be 
accelerated and sensory neurons could be generated within 8 days (Chambers et al., 
2009). Part of the confusion could stem from the fact that when transferring procedures 
from mouse PSCs: There, FGF signaling is crucial and blockage is detrimental for 
neural induction. It should be noted that mouse PSCs exist in a “naïve” state that 
appears to be developmentally slightly upstream of the “primed” pluripotent state of 
hiPSCs. In order to differentiate into neuroectoderm, mouse PSCs therefore have to 
transition through the primed state, which is, like hiPSCs, dependent on FGF signaling 
(Greber et al., 2011). 
On the other hand, FGF signaling plays an important role after neural induction during 
the expansion phase, in which NPCs can be expanded and stabilized (Elkabetz et al., 
2008; Falk et al., 2012; Shi et al., 2012a; Yao et al., 2006; Zhang et al., 2001). 
 
In 2017, a very fast differentiation protocol was published by Qi et al.: In their protocol, 
morphologically mature cortical neurons could be derived within 16 days of 
differentiation by the use of the accelerating effect by, among others, inhibiting the 
FGF2 pathway (Qi et al., 2017). 
The drawback of this protocol is that no progenitor exists as no expansion step is 
included in this protocol (Qi et al., 2017). Such an NPC type could be used for genetic 
manipulation or freezing in between so that the initial step of differentiation could be 
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skipped. Further, a colleague tried to reproduce the protocol. Morphologically, only 2 
out of 5 differentiation attempts were successful (data not shown).  
 
Differentiation of hPSCs into neurons can be performed, as described earlier, in 3D or 
in 2D culture, both approaches bear their advantages and disadvantages: 3D 
recapitulates the situation in vivo more physiologically. The drawback is, that several 
cell types are formed and that it is impossible to derive a single cell type of interest 
(Lancaster and Knoblich, 2014). Therefore, differentiation in 2D has the advantage that 
single cell types can be formed more accurately with less foreign cell type 
contamination and better control over cell morphology and signaling can be 
maintained.  
 
Therefore, here, the aim was to develop a robust, and quick 2D differentiation protocol 
which is xeno-free and chemically-defined and can ideally be applied to any available 
hiPSC line. 
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2 MATERIALS AND METHODS 
2.1 Instruments 
Instruments Company 
ArrayScan Thermo Fisher 
Maestro Pro Axion Biosystems 
NanoDrop Thermo Fisher 
QiaCube Qiagen 
QuantStudio 7 Flex Real Time PCR 
System 
Thermo Fisher 
Biomark HD Fluidigm 
Juno Fluidigm 
 
 
2.2 Cell culture 
2.2.1 Dishes and flasks 
Plate format/flask format Company Order number Growth Area 
6-well plate  Nunc 140675 9.5cm² 
12-well plate Nunc 150628 3.5cm² 
96-well plate µclear Greiner 655950 0.34cm² 
T75 flask Greiner 658175 75cm² 
T175 flask Greiner 660175 175cm² 
 
 
2.2.2 Cell lines 
hiPSC line Referred to as Source Phenotype Sex Age Reprogram-
ming 
method 
Reprogram-
ming 
factors 
SBAD3 Cl1 hiPSC_1 StemBANCC healthy 
control line 
female 31 
years 
Sendai virus OSKM 
SFC840 
Cl3 
hiPSC_2 StemBANCC healthy 
control line 
female n/a Sendai virus OSKM 
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SFC086 
Cl1 
hiPSC_3 StemBANCC healthy 
control line 
female n/a Sendai virus OSKM 
SFC808 
Cl4 
hiPSC_PSEN1 StemBANCC PSEN-1 
intron 4 
deletion 
female n/a Sendai virus OSKM 
MAPT WT 
ClF9 
(IPSC0028) 
hiPSC_4 Sigma healthy 
control line 
female 24 
years 
retroviral  OSKM 
MAPT WT 
FsRed 
clone 1E11 
hiPSC_5 engineered 
from 
IPSC0028 
healthy 
control line, 
fusion red 
tag at 
MAPT 
locus 
female 24 
years 
retroviral  OSKM 
MAPT Pbi 
Ebi FsRed 
clone 1D9 
hiPSC_MAPT engineered 
from 
IPSC0028 
Biallelic 
P201S 
biallelic 
E10-16 
female 24 
years 
retroviral  OSKM 
 
2.2.3 Cell culture media ingredients, coatings and buffers  
Product Company Order number 
Media ingredients   
Accutase in DPBS Life Technologies A11105-01 
Advanced DMEM/F12 Life Technologies 12634-028 
B27 supplement w/o vitamin A (50x), 
serum-free 
Life Technologies 12587-010 
CTS-B27 (50x), serum-free Life Technologies A1486701 
DMEM/F12 Life Technologies 31330-095 
Dimethyl sulphoxide (DMSO) Serva 20385.01 
Essential 6 Medium Life Technologies A1516501 
Essential 8 Flex Kit Life Technologies A-11105-01 
L-Glutamine, 200mM Life Technologies 25030-024 
Neurobasal medium Life Technologies 21103-049 
N2 supplement (100x), serum-free Life Technologies 17502-48 
Penicillin/Streptomycin (Pen/Strep) (100x) Life Technologies 15140-122 
Coatings reagents   
Matrigel, hESC-qualified Corning 354277 
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Product Company Order number 
recombinant human (rh) Laminin-521 
(LN521) 
BioLamina LN521-03 
poly-L-ornithine solution, 0.01% Sigma-Aldrich P4957 
rh Vitronectin (VTN-N) Thermo Fisher 
Scientific 
A14700 
Buffers and liquids   
distilled water Life Technologies 15230-071 
Dulbecco’s phosphate buffered saline 
(DPBS) with Mg2+ & Ca2+ 
Life Technologies 14040-091 
DPBS w/o Mg2+ & Ca2+ Life Technologies 14190-169 
 
 
2.2.4 Small molecules and organic molecules 
Small molecule Company Catalog 
number 
CAS 
number 
Mode of action 
ascorbic acid Sigma-Aldrich A4544 50-81-7 Vitamin C, reducing 
agent, antioxidant 
CHIR99021 AbbVie internal 
compound 
- 252917-
06-9 
Inhibitor of Glycogen 
Synthase 3 (GSK3) 
Cyclopamine Tocris 1623 4449-51-
8 
Sonic hedgehog (SHH) 
inhibitor 
DAPT Sigma-Aldrich D5942 208255-
80-5 
γ-secretase inhibitor 
dbcAMP Sigma-Aldrich D0627-1G 16980-
89-5 
cAMP analogue, 
penetrates cell 
membrane 
Dorsomorphin 
dihydrochloride 
Tocris 3093 1219168-
18-9 
AMPK inhibitor, BMP 
type I receptor inhibitor 
IWP2 Tocris 3533 686770-
61-6 
PORCN inhibitor, 
inhibits processing and 
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Small molecule Company Catalog 
number 
CAS 
number 
Mode of action 
secretion of WNT 
molecules 
LDN193189 Sigma-Aldrich SML0559-
5MG 
1062368-
24-4 
ALK2 and 3 inhibitor 
PD0325901 Tocris 4192 391210-
10-9 
MEK1/2 inhibitor 
SB431542 Tocris 1614 301836-
41-9 
Inhibitor of TGF-β type I 
receptor/ALK5, ALK4, 
ALK7 inhibitor 
XAV939 Tocris 3748 284028-
89-3 
Tankyrase inhibitor 
Y-27632 Calbiochem 688000-
10MG 
146986-
50-7 
P160 ROCK inhibitor 
 
 
2.2.4.1 Preparation of small molecules and organic molecules 
Powder of small molecules and organic molecules was diluted according to the 
manufacturer’s protocol, aliquoted in tubes and stored at -20°C. Aliquots were used 
within 6 months and then prepared freshly. Thawed aliquots were stored in the fridge 
and used within several days. 
 
Small molecule Stock 
concentration 
Working 
concentration  
Preparation 
Ascorbic Acid 200µM 200nM solved in sterile, distilled water, 
sterile-filtered 
CHIR99021 10mM 0.5µM – 3µM solved in DMSO 
Cyclopamine 5mM  5µM solved in DMSO 
DAPT 10mM 10µM solved in DMSO 
dcAMP 100mM 500µM solved in sterile, distilled water, 
sterile-filtered 
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Small molecule Stock 
concentration 
Working 
concentration  
Preparation 
Dorsomorphin 
dihydrochloride 
10mM 1µM solved in DMSO 
IWP2 5mM 1µM solved in DMSO 
LDN193189 
hydrochloride 
0.5mM 0.5µM solved in DMSO 
PD0325901 10mM 1µM solved in DMSO 
SB431542 10mM 10µM solved in DMSO 
XAV939 10mM 2µM solved in DMSO 
Y-27632 5mM 10µM solved in sterile, distilled water 
 
 
2.2.5 Proteins 
Protein Company Order 
Number 
Brain-derived neurotrophic factor (BDNF), 
animal-free 
Peprotech AF-450-02 
Human Serum Albumin(HSA), non-denatured Merck 126654 
Fibroblast growth factor (FGF)- basic,  
animal-free 
R&D Systems AF-100-18B 
Glial-derived neurotrophic factor (GDNF), 
 animal-free 
Peprotech AF-450-10 
WNT-3a R&D Systems 5036-WN 
 
 
2.2.5.1 Preparation of proteins 
Lyophilized proteins were diluted according to the manufacturers protocol: Proteins 
were diluted to 100µg/mL in sterile water. Then, further dilution was prepared in DPBS 
containing Mg2+ and Ca2+ with 0.1% of HSA as a carrier protein. Solutions were 
aliquoted in tubes and stored at -20°C. 
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Protein Stock 
concentration 
Working  
concentration 
Preparation 
FGF-basic 
(FGF) 
10µg/mL 10ng/mL first in water, then in DPBS with 
carrier protein 
BDNF 10µg/mL 10ng/mL first in water, then in DPBS with 
carrier protein 
GDNF 10µg/mL 10ng/mL first in water, then in DPBS with 
carrier protein 
 
 
2.2.6 Preparation of media 
2.2.6.1 E8flex Medium 
E8flex medium was prepared as recommended by the supplier: From the basal E8 
medium, 10mL of medium were removed and 10mL of the E8 flex supplement were 
added. Medium was stored at 4°C and used no longer than for 4 weeks. 
2.2.6.2 Basal Medium (BM) 
Ingredient Stock concentration Dilution Final concentration 
DMEM/F12 1x 1:2 0.5x 
Neurobasal 1x 1:2 0.5x 
N2 supplement 100x 1:200 0.5x 
B27 supplement 50x 1:100 0.5x 
Pen/Strep 100x 1:100 1x 
Glutamine 200mM 1:200 1mM 
 
After preparation, medium was sterile-filtered and stored at 4°C until use, but no longer 
than for 4 weeks. 
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2.2.6.3 Maturation Medium (MM) 
Ingredient Stock 
concentration 
Dilution Final 
concentration 
BM 1x - 1x 
dbcAMP 100mM 1:200 500µM 
ascorbic acid 200µM 1:1000 200nM 
LN521 100µg/mL 1:100 1µg/mL 
BDNF 10µg/mL 1:1000 10ng/mL 
GDNF 10µg/mL 1:1000 10ng/mL 
 
Medium was stored at 4°C until use, but no longer than for 2 weeks. 
Within the first days of maturation, medium was supplemented by DAPT and PD. 
 
 
2.2.7 Coating of dishes and flasks 
Following amount of coating solution was administered to the flasks/wells of a cell 
culture plate: 
 
Well/Flask Coating volume 
T175 17.5mL 
T75 7.5mL 
6-well 1mL 
12-well 0.5mL 
96-well 60µL 
 
2.2.7.1 Preparation of Matrigel aliquots 
Matrigel was thawed slowly on ice in the fridge overnight. Then, aliquots were prepared 
according to the manufacturer’s dilution factor provided: The aliquots should have the 
amount necessary to dissolve in 25mL of DMEM/F12 medium.  
After aliquoting, which was performed on ice, aliquots were stored at -20°C 
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2.2.7.2 Coating with Matrigel 
Frozen Matrigel aliquots were dissolved in 25mL of cold DMEM/F12, mixed and flasks 
or wells were quickly coated. Coated plastic were was stored in an incubator at 37°C 
for 2 to 4 hours. In case of long-term storage, plastic ware was sealed with parafilm 
and stored in the fridge until use, but not for longer than 2 weeks. 
 
2.2.7.3 Coating with LN521 
Cell culture dishes were coated with 5µg/mL LN521 by diluting the stock in DPBS with 
Mg2+ and Ca2+. Coating solution was simply added to the flasks or wells of the cell 
culture plate, the dishes were sealed with parafilm to prevent drying and stored at 4°C 
on a shaker for at least 2 hours, but not longer than 3 weeks. After a week in fridge, 
coating solution needed to be supplemented with DPBS with Mg2+ & Ca2+ to prevent 
drying from long term storage.  
 
2.2.7.4 Coating with VTN-N 
VTN-N was solved 1:200 in DPBS with Mg2+ and Ca2+ to derive a 2.5µg/mL coating 
solution. Plastic ware was coated and stored in the incubator for 2 hours until use. In 
case of long-term storage, plastic ware was sealed with parafilm and stored in the 
fridge until use, but not for longer than 2 weeks. 
2.2.7.5 Double-coating with poly-L-ornithine (PLO) and LN521 
Cell culture dishes were first coated with poly-L-ornithine (PLO) by diluting the stock-
solution to 0.001% of PLO with DPBS with Mg2+ and Ca2+. Dishes were sealed with 
parafilm and stored at 4°C on a shaker for at least 4hrs or overnight. Then, coating 
was aspirated, dishes were washed once with DPBS with Mg2+ and Ca2+ and then, 
coated with LN521 as described before. 
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2.3 Cell culture procedures 
2.3.1 Culturing & passaging of cells 
hiPSCs were grown on plastic dishes or well plates coated with 5µg/mL of recombinant 
human LN521.  
Cells were grown until 70-100% of confluency and were passaged then. For 
passaging, cells were washed with DPBS w/o Mg2+ & Ca2+, detached and singularized 
by incubation with Accutase for 5-8min at 37°C, transferred to medium and centrifuged 
at 300xg for 5min and replated on a new dish in E8flex medium supplemented with 
10µM of Y-27632. The next day or a few hours later, medium was changed to E8flex 
only to get rid of Y-27632. E8flex medium was changed every day or every other day, 
depending on medium consumption. In case of weekends medium change was 
performed every 2.5 days. The splitting ratio or seeding density was adjusted to the 
needs. Cells were split between a ratio of 1:6 to 1:12 or seeded as 10 000 to 
35 000cells/cm² depending on how quick they proliferated and when the cells were 
needed for a differentiation round. 
2.3.2 Freezing of cells 
Cells were passaged as described before. After the centrifugation step, cells were 
resuspended in freeze medium consisting of the culturing media supplemented with 
10% DMSO and 10µM Y-27632 in a cryo vial. The vial was quickly placed into a 
controlled rate freezing container and transferred to -80°C for a few days. Then, cells 
were transferred to liquid nitrogen until use. 
2.3.3 Thawing of cells 
Cryo tubes with frozen cells were quickly thawed in a 37°C-water bath and transferred 
into culture medium. Then, cells were centrifuged as described, resuspended carefully 
in culture medium supplemented with 10µM Y-27632 and plated on a coated dish. A 
minimum of 4 hours later or the next day, cell medium was replaced by medium without 
Y-27632. 
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2.3.4 Differentiation of cells 
If not otherwise indicated, cells were induced for 6 days, expanded for 4 days and 
finally matured until use (Figure 10) 
 
2.3.4.1 Induction  
For induction, cells were seeded between 200 000 – 500 000cells/cm² in E8flex 
supplemented with 10µM Y-27632 onto LN521-coated dishes, if not indicated 
otherwise. As soon as the cells formed a fully confluent layer, preferable the day after 
seeding, induction was started with E6 medium supplemented with small molecules as 
indicated. On day 2, a 50%-mixture of E6 medium and basal medium (BM) was 
prepared and supplemented with small molecules as indicated. On day 3, medium was 
replaced by BM supplemented with the small molecules as indicated. Medium change 
was performed every day except on weekends, when medium was changed every 2.5 
days. If not indicated otherwise, RNA samples were collected at D0, D3 and D6. The 
same days, 96-well plates were fixed for immunofluorescence analysis if needed. 
 
2.3.4.2 Expansion 
If not indicated otherwise, a part of the cells from induction were expanded from day 6 
onwards. For expansion, medium was changed to expansion medium which consists 
of BM supplemented with pathway modulators as indicated. Usually, FGF only, FGF 
and IWP2 or FGF together with IWP2 and Cyclopamine (Cyclo) were used. 
 
Figure 16: Differentiation scheme from hiPSCs towards cortical neurons. 
If not indicated otherwise, cells were seeded at D-1 in E8flex supplemented with ROCK inhibitor. The next day, 
induction was started for 6 days by switching to E6 medium supplemented with inhibitors of BMP, MEK and 
WNT pathways. The inhibitors used were mainly Dorsomorphin, PD and IWP2 if not otherwise indicated. E6 
medium was gradually switched towards BM containing the same inhibitors until D6. After induction, expansion 
followed for 4 days. During expansion, the derived progenitors were fed by BM supplemented with FGF and 
WNT inhibition by IWP2. At D10 of differentiation, cells were fed with maturation medium (MM) supplemented 
with MEK inhibitor and DAPT for 7 to 14 days. Subsequently, MM only was administered. ROCK-i: Y-27632 
(also known as ROCK inhibitor), BM: basal medium, MM: maturation medium. 
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2.3.4.3 Maturation 
After 4 days of expansion, cells were fed with maturation medium supplemented with 
PD and DAPT. After 4 days, cells were reseeded onto PLO/ LN521 coated plates in 
MM supplemented with PD, DM and 10µM Y-27632. The next day, medium was 
changed to get rid of the Y-27632. From then on, medium was changed twice a week, 
every 3-4 days. As soon as all cells revealed a neuronal morphology, MM only was 
added without any supplements. This was the case after 1-2 weeks. 
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2.4 Aβ-ELISA 
2.4.1 Aβ MSD ELISA materials 
 
Reagents/Kits Company Order number 
V-PLEX Kit Aβ-ELISA by Aβ Peptide Panel 1 
(6E10) 
Meso Scale 
Discovery 
K15200G 
 
2.4.2 Collection of supernatants for Aβ-ELISA 
Supernatant of cells was collected into falcon tubes or Eppendorf tubes and 
centrifuged at 300xg for 3min to get rid of cells or cell debris. Supernatant from 
centrifugation was frozen at -80°C until use. 
 
2.4.3 Performing of Aβ-ELISA by Aβ Peptide Panel 1 (6E10) V-PLEX Kit 
The Aβ-ELISA was performed according to the supplier’s protocol: 
2.4.3.1.1 Blocking 
First, the wells of the MSD-ELISA plates were blocked with 150µL of Diluent 35. Plates 
were sealed and incubated with shaking at room temperature for 1 hour. 
2.4.3.1.2 Washing and sample addition 
Wells were washed 3 times with 150µL of 1x MSD Wash Buffer. Then, 25µL of 1x 
detection antibody solution was added into the wells with subsequent adding of 25µL 
of 7 calibrator solutions and 1 zero-calibrator were prepared. The calibrator stock 
solution was prepared by adding the three Aβ-peptides Aβ38, Aβ40 and Aβ42 into 
Diluent 35. This Aβ calibrator stock was diluted 1:4 in Diluent 35 to obtain 7 calibrator 
solutions. As the zero calibrator, Diluent 35 only is used. Further, 25µL of the undiluted 
supernatant samples were added as triplicates onto the plates. The plate was sealed 
and incubated on a shaker for 2 hours. 
2.4.3.1.3 Detection 
After incubation, plate was washed again with 150µL/well of 1x MSD Wash Buffer. 
Then, 150µL/well of Read Buffer T was added and the plate was directly analyzed on 
an MSD instrument. 
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2.4.3.1.4 Data analysis and statistics 
The measured data were analyzed by MSD Discovery Workbench Software. 
Concentrations of the three different Aβ-peptides Aβ38, Aβ40 and Aβ42 in the samples 
could be determined by the calibrator dilutions. The concentrations of Aβ40 and Aβ42 
in the samples were used to calculate the Aβ42 to Aβ40 ratio. 
This ratio was used for statistical analysis to determine whether it changes over time 
in an hiPSC line or if it changes between a healthy control hiPSC line and a 
PSEN1-disease line which is known to produce more of the Aβ42 peptide. Statistical 
analysis was performed with GraphPad Prism 7 on the technical triplicates of the 
samples. First, the samples were tested for normal distribution by Shapiro-Wilk test. In 
case of equal variances, an unpaired t-test was used. In case of unequal variances, 
the Welch’s t-test was used to determine significant differences between the samples. 
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2.5 Multielectrode array (MEA) analysis 
2.5.1 MEA materials 
Product Company Order number 
CytoView MEA 48 plate, black Axion Biosystems M768-tMEA-48B 
 
2.5.2 Coating of MEA-plates with PLO and LN521 
MEA plates were coated according to the manufacturer with some modifications: 
Wells were coated with PLO-solution overnight at room temperature, then washed with 
DPBS with Mg2+ and Ca2+. Then, 5µg/mL LN521 coating was prepared in MM with all 
ingredients supplemented, means supplemented with Y-27632, PD and DAPT. A 5µL-
drop was placed into the middle of the dry well and incubated in a cell culture incubator 
for 1hr. After incubation, cells were plated directly. 
2.5.3 Seeding of cells into MEA plate 
After 1hr of LN521 coating incubation a 5µL cell suspension drop containing 
75 000 cells were pipetted into the coating drop. Cells were incubated for 1hr in the 
drop. Afterwards, 300µL of cell culture medium was filled carefully into the wells. 
2.5.4 MEA measurement 
For assessing the functional activity of neurons, the MEA plate with attached neurons 
could be measured in the Maestro Pro MEA device and recordings were recorded by 
the AxIS Navigator Software. 
Before recording, the electrode plate was placed into the Maestro Pro MEA device for 
30min. Then, 3 recordings were programmed, each recording took 10min and 
recordings were started every 30min. For analysis, the third of the 3 recordings was 
analyzed and compared to other time points of measurement. Data were analyzed by 
the AxIS Metric Plotting tool. 
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2.6 Immunofluorescence staining 
2.6.1 Immunofluorescence staining materials 
Solution/buffers Company Order number 
Dulbecco’s phosphate buffered saline 
(DPBS) with Mg2+ & Ca2+ 
Life Technologies 14040-091 
Bovine serum albumin (BSA) Sigma Aldrich A9647-50G 
Fetal calf serum (FCS) Sigma Aldrich C8056 
Sodium azide  Sigma Aldrich S2002-25G 
Triton X-100 Sigma Aldrich X100 
 
2.6.2 Buffers 
4% (w/v) formaldehyde (FA) 
 in DPBS with Mg2+ & Ca2+ 
 
Block/perm solution 
10% FCS 
1% BSA  
0.2% Triton X-100 
 in DPBS with Mg2+ & Ca2+ 
 
Antibody solution 
0.1% BSA 
 in DPBS with Mg2+ & Ca2+ 
 
0.1% (w/v) sodium azide 
 in DPBS with Mg2+ & Ca2+ 
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2.6.3 Primary antibodies 
Antigen Antibody Name Species 
and 
Isotype  
Clone Clonality Company Order 
number 
Stock 
concentra-
tion 
Working 
dilution 
Working 
concentra-
tion 
AP2α AP-2 alpha 
supernatant 1mL 
mouse 
IgG1 (κ-
light chain) 
n.a. monoclonal Developmental 
Studies 
Hybridoma 
Bank 
5-E 4 28µg/ml 1:200 0.14µg/mL 
Cytokeratin 
18 
Anti-Cytokeratin 
18 antibody 
ab52948 
rabbit IgG - polyclonal Abcam ab52948 1mg/mL 1:300 3.3µg/mL 
FOXG1 Anti FOXG1 
antibody - ChIP 
Grade ab18259 
rabbit IgG - polyclonal Abcam ab18259 0.7 - 
1mg/mL 
1:150 - 
1:300 
4.6µg/mL – 
2.3µg/mL 
MAP2 Monoclonal Anti-
MAP2 (2a + 2b) 
Clone AP-20 
mouse 
IgG1 
AP-20 monoclonal Sigma-Aldrich M1406-
.2ML 
n/a 1:200 n/a 
MAP2 Anti-MAP2 
antibody ab5392 
chicken 
IgY 
 polyclonal Abcam ab5392 19mg/mL 1:10 000 1.9µg/mL 
Oct-4A Oct-4A (C30A3) 
Rabbit mAb 
rabbit IgG C30A3 monoclonal Cell Signaling 2840 n/a 1:200 n/a 
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Antigen Antibody Name Species 
and 
Isotype  
Clone Clonality Company Order 
number 
Stock 
concentra-
tion 
Working 
dilution 
Working 
concentra-
tion 
Otx2 Human Otx2 
Antibody 
goat IgG - polyclonal R&D Systems AF1979 0.2mg/mL 1:250 0.8µg/mL 
PAX6 Purified anti-Pax6 
Antibody 
rabbit IgG Poly19013 polyclonal BioLegend 901301 2mg/mL 1:150 – 
1:300  
13µg/mL – 
6.6µg/mL 
PAX6 Pax6, bioreactor 
supernatant, 
0.1mL  
mouse 
IgG, kappa 
light chain 
n.a. monoclonal Developmental 
Studies 
Hybridoma 
Bank 
AB 
528427 
500µg/L 1:60-
1:80 
8.3µg/mL – 
6.25µg/mL 
SATB2 Anti-SATB2 
antibody 
[SATBA4B10] 
ab51502 
mouse 
IgG1 
SATBA4B10 monoclonal Abcam ab51502 0.1mg/mL 1:100 1µg/mL 
SOX1 Human/Mouse/Rat 
SOX1 Antibody 
goat IgG - polyclonal R&D Systems AF3369 0.2mg/mL 1:200 2µg/mL 
SOX2 Sox2 (D6D9) 
XP(R) Rabbit mAb  
rabbit IgG D6D9 monoclonal Cell Signaling 3579S n/a 1:200 - 
1:400 
n/a 
SOX10 Human SOX10 
Antibody 
goat IgG - polyclonal R&D AF2864 0.2mg/mL 1:100 2µg/mL 
3R Tau Anti-TAU (3-
repeat isoform 
Mouse IgG clone 
8E6/C11 
monoclonal Millipore 05-803 n/a 1:2000 n/a 
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Antigen Antibody Name Species 
and 
Isotype  
Clone Clonality Company Order 
number 
Stock 
concentra-
tion 
Working 
dilution 
Working 
concentra-
tion 
RD3) clone 
8E6/C11 
Tau Anti-Tau antibody 
(ab64193) 
rabbit - polyclonal Abcam Ab64193 0.2mg/mL 1:500 0.4µg/mL 
TBR1 Anti-TBR1 
antibody 
(ab31940) 
rabbit IgG - polyclonal Abcam ab31940 1mg/mL 1:300 3.3µg/mL 
Tubulin β3 
(TUBB3) 
Purified anti- 
Tubulin β3 
(TUBB3) Antibody 
mouse 
IgG2a 
TUJ1 monoclonal Biolegend  801202 1mg/mL 1:1000 1µg/mL 
vGAT1 
(SLC32A1) 
VGAT Rabbit 
polyclonal 
antibody 
rabbit IgG - polyclonal Proteintech 14471-1-
AP 
0.15mg/mL 1:300 0.5µg/mL 
vGLUT2 VGLUT2 (D7D2H) 
Rabbit mAb 
rabbit IgG D7D2H monoclonal Cell Signaling 71555 n/a 1:100 n/a 
 
All antibodies were prepared as recommended in the datasheet prior to dilution for staining. 
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2.6.4 Secondary antibodies and other stains 
Antibody  Company Order number Stock 
concentration 
Working 
dilution 
Working 
concentration 
Alexa Fluor488-conjugated AffiniPure Donkey Anti 
Rabbit IgG (H+L)  
Jackson-
ImmunoResearch 
Laboratories 
711-545-152 1.5mg/mL 1:500 3µg/mL 
Cy3-conjugated AffiniPure Donkey Anti Goat IgG 
(H+L) 
Jackson-
ImmunoResearch 
Laboratories 
705-165-147 1.5mg/mL 1:500 3µg/mL 
Cy™5 AffiniPure Donkey anti mouse Cy5 Jackson-
ImmunoResearch 
Laboratories 
715-175-151 1.5mg/mL 1:500 3µg/mL 
Alexa Fluor 647 conjugated AffiniPure Donkey anti 
mouse IgG (H+L) 
Jackson-
ImmunoResearch 
Laboratories 
715-605-150 1.5mg/mL 1:500 3µg/mL 
Hoechst 33342 trihydrochloride trihydrate Invitrogen H3570 10mg/mL 1:2000 5µg/mL 
Donkey anti-Mouse IgG (H+L) secondary 
Antibody, Alexa Fluor 488 
Invitrogen A21202 2mg/mL 1:1000 2µg/mL 
Donkey anti-Rabbit IgG (H+L) secondary 
Antibody, Alexa Fluor 488 
Invitrogen A1206 2mg/mL 1:1000 2µg/mL 
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Antibody  Company Order number Stock 
concentration 
Working 
dilution 
Working 
concentration 
Donkey anti-Goat IgG (H+L) secondary Antibody, 
Alexa Fluor 555 
Invitrogen A21432 2mg/mL 1:1000 2µg/mL 
Donkey anti-Chicken IgY (H+L) secondary 
Antibody, Alexa Fluor 555 
Invitrogen A21437 2mg/mL 1:1000 2µg/mL 
Donkey anti-Rabbit IgG (H+L) secondary 
Antibody, Alexa Fluor 647 
Invitrogen A31573 2mg/mL 1:1000 2µg/mL 
 
2.6.4.1 Reconstitution of secondary antibodies from Jackson ImmunoResearch Laboratories 
Antibodies were rehydrated in 400µL of water and 400µL of glycerol, aliquoted & stored at -20°C until use. 
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2.6.5 Immunofluorescence staining of cells 
2.6.5.1 Fixation of cells 
Depending on the cell type to be fixed, cells were washed with DPBS containing Mg2+ 
and Ca2+ and fixed with 4% formaldehyde in DPBS for 15min. In case of neurons to 
prevent neurite detachment, cells were not washed and fixed for 15min with 4% 
formaldehyde in DPBS by adding equal volume of 8% formaldehyde to cells in their 
medium. After incubation, cells were washed with DPBS with Mg2+ and Ca2+ and stored 
in 0.1% Na-azide solution in the fridge until further processing. 
2.6.5.2 Blocking and permeabilization of cells 
Fixed cells were washed with DPBS containing Mg2+ and Ca2+ and incubated with 
block/perm solution for 30-60min.  
2.6.5.3 Incubation of cells with primary antibody 
After blocking and permeabilization, cells were washed with DPBS containing Mg2+ 
and Ca2+. Then, cells were incubated with antibody solution that contained the primary 
antibodies for labeling the desired antigen overnight at 4°C. In case of control wells, 
cells were incubated with antibody solution only. 
2.6.5.4 Incubation of cells with secondary antibody 
After incubation of cells with primary antibody, cells were washed with DPBS 
containing Mg2+ and Ca2+ for three times and then incubated with secondary antibody 
that bind to the corresponding primary antibodies. Cells were incubated for 1hr. Then, 
cells were washed for 3 times and stored in 0.1% Na-azide until imaging. 
2.6.5.5 Image acquisition by ArrayScan 
For image acquisition by the ArrayScan, the HCS-software was used. Settings were 
adjusted for the different stainings, such as plate format and form factor that was stored 
already by the ArrayScan software, magnification, that was usually set to 20x, and 
exposure time that was adjusted manually or by the help of the auto-exposure 
algorithm. 
In case of nuclear staining, exposure percentage was set to 25, in case of neurite 
staining, it was set to 45. This percentage was used to adjust exposure time. 
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After exposure time was adjusted, settings were saved and plates with the different 
stainings were acquired in an automated way by the help of the Momentum software. 
Image adjustment was also performed by the HCS-software. For the input settings of 
brightness and contrast, the negative controls were used. 
 
  
Materials and Methods 
43 
 
2.7 RNA purification, reverse transcription and qPCR  
2.7.1 RNA purification and PCR reagents 
Kits or ingredients Supplier Order Number 
RNeasy Plus Mini Kit Qiagen 74106 
QIAshredder Qiagen 79656 
SuperScript IV VILO MasterMix with edDNase 
Enzyme 
Thermo Fisher 
Scientific 
11766500 
TaqMan Fast Universal PCR Master Mix (2x), no 
AmpErase UNG 
Thermo Fisher 
Scientific 
4352042 
RapidOut DNA Removal Kit Thermo Fisher 
Scientific 
K2981 
Transcriptor First Strand cDNA Synthesis Kit Roche 04 896 866 001 
MicroAmp EnduraPlate Optical 96-Well Clear 
Reaction Plates with Barcode 
Thermo Fisher 
Scientific 
4483354 
TaqMan Fast Advanced Master Mix Thermo Fisher 
Scientific 
4444557 
Sample loading reagent 20x Fluidigm 100-7610 
Assay loading reagent 2x Fluidigm 100-7611 
 
2.7.2 TaqMan probe assays 
Gene Company Assay ID Assay ID used at 
FNC 
ACTB Thermo Fisher Hs99999903_m1 - 
B2M Thermo Fisher Hs00984230_m1 - 
EMX2 Thermo Fisher - Hs00244574_m1 
FOXG1 Thermo Fisher Hs01850784_s1 Hs01850784_s1 
GAPDH Thermo Fisher Hs99999905_m1 Hs02786624_g1 
LMX1A Thermo Fisher Hs00892663_m1 Hs00898455_m1 
NANOG Thermo Fisher Hs02387400_g1 Hs02387400_g1 
OTX2 Thermo Fisher Hs00222238_m1 Hs00222238_m1 
PAX6 Thermo Fisher Hs00240871_m1 Hs01088114_m1 
POU5F1 (OCT4) Thermo Fisher Hs04260367_gH Hs04260367_gH 
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RPL13 Thermo Fisher - Hs00744303_s1 
SOX10 Thermo Fisher Hs00366918_m1 Hs00366918_m1 
UBC Thermo Fisher - Hs01871556_s1 
WNT1 Thermo Fisher Hs00180529_m1 - 
WNT3 Thermo Fisher Hs00902257_m1 - 
WNT3A Thermo Fisher Hs00263977_m1 - 
 
2.7.3 RNA isolation from cell culture samples 
RNA isolation and purification were performed by the help of the RNeasy Plus Mini Kit 
and the QIAshredder Kit from Qiagen. 
RNA was usually collected from cells grown in 12- or 6-wells of a plate. Wells were 
washed with DPBS without Mg2+ and Ca2+. Then, cells were lysed with RLT-Plus buffer 
included in the RNeasy Plus Mini Kit. Lysed cells in RLT-Plus buffer were collected into 
Eppendorf tubes and stored at -20°C for short term storage, at -80°C for long term 
storage until use. 
Frozen samples were thawed on ice and homogenized by using the QIAshredder Kit: 
350µL of the lysed samples were transferred into a QIAshredder homogenizer which 
was placed into a collection tube and centrifuged at full speed for 2min. The 
homogenized lysate was then further processed in the QiaCube which performed the 
following steps in an automated way: 
The homogenized lysate was transferred to a gDNA Eliminator spin column. The 
column was centrifuged at 8000xg for 30sec. The flow-through was further used and 
same volume of 70% EtOH was added and mixed. The solution was pipetted into an 
RNeasy mini column and centrifuged at 8000xg for 15sec. The RNA sample was bound 
to the column, flow-through was discarded. 
700µL of RW1 buffer was added to the RNeasy mini column, everything was 
centrifuged at 8000xg for 15sec and flow-through was discarded. 
Then, column was washed twice with 500µL of RPE buffer by centrifugation at 8000xg 
for 2min. 
Then, RNeasy mini column was transferred to a fresh collection tube, 30µL of water 
was pipetted, column was centrifuged for 1min at 8000xg and eluate containing the 
mRNA was used for further processing. 
The mRNA prepared by the QiaCube was measured on the NanoDrop to determine 
the RNA content. 
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The next step was digestion of genomic DNA. This step is performed depending on 
the cDNA synthesis procedure used. 
DNA digestion with RapidOut DNA Removal Kit was used together with Transcriptor 
First Strand cDNA Synthesis Kit. 
DNA digestion with ezDNAse Enzyme was used together with SuperScript IV VILO 
MasterMix, as they come together in one kit. 
 
2.7.4 DNA digestion with RapidOut DNA Removal Kit with subsequent cDNA 
transcription by Transcriptor First Strand cDNA Synthesis 
For DNA digestion, the RapidOut DNA Removal Kit was used which contains DNase I 
and DNase Removal Reagent to get rid of the DNase. 
DNA removal is necessary to avoid amplification of genomic DNA and therefore 
leading to false results in the qPCR process. 
For DNA removal, DNase I was added to RNA samples, 0.5µL of DNase I was needed 
per 10µL reaction volume: 
 
Component Amount/volume 
RNA sample Up to 8.5µL (1µg) 
10x DNase buffer with MgCl2 1x 
DNase I 0.5µL (0.05U/µL)  
water up to 10µL 
Total volume 10µL 
 
The mixture was incubated at 37°C for 30min. After incubation, sample was cooled 
down on ice. 
To remove the DNase, DNase Removal Reagent (DRR) was added to the sample and 
incubated for 2min at room temperature so that the DRR bound the DNase I. 
Occasionally, the mixture was mixed. Then, DRR was pelleted by centrifugation at 
800xg for 1min to remove DNase I. 
The supernatant that contained the RNA was carefully collected into a fresh RNAse-
free tube. 
Afterwards, cDNA synthesis was performed by the Transcriptor First Strand cDNA 
Synthesis  
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2.7.5 cDNA Synthesis with Transcriptor First Strand cDNA Synthesis Kit 
The cDNA synthesis was performed by the help of the Transcriptor First Strand cDNA 
Synthesis Kit. 
2.7.5.1 Denaturation 
cDNA, dT15 primer and water were mixed, samples were placed into a PCR-Cycler 
and heated up to 65°C for 10min. Afterwards, samples were cooled on ice. 
2.7.5.2 Synthesis 
For cDNA synthesis, a master mix of following ingredients was prepared: 
 
Component Final amount 
5x Transcriptor Reverse Transcriptase 
Reaction Buffer 
1x 
Protector RNase Inhibitor (40U/µL) 1U/µL 
Deoxynucleotide Mix 1mM 
Transcriptor Reverse Transcriptase 0.5U/µL 
DTT 5mM 
Total volume 40-60µL 
 
The master mix was added to the denatured mixture. Everything was mixed and placed 
into a PCR Cycler. Samples were heated up to 50°C for 1hr and then heated up to 
85°C for 5min. Afterwards, samples were cooled on ice or stored at -20°C until further 
use. 
2.7.6 DNA digestion with ezDNAse Enzyme with subsequent cDNA transcription by 
with SuperScript IV VILO MasterMix 
Samples were mixed with 1x ezDNase Buffer and ezDNase enzyme: 
 
Component Final amount 
10x ezDNase Buffer 1µL 
ezDNase enzyme 1µL 
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RNA sample up to 8µL (1pg – 2.5µg total 
RNA) 
nuclease-free water to 10µL 
Total volume 10µL 
Mixture was incubated for 2min at 37°C and incubated on ice until further use. 
Afterwards, cDNA synthesis was performed by using the SuperScript IV VILO 
MasterMix 
2.7.6.1 cDNA Synthesis with SuperScript IV VILO MasterMix 
SuperScript IV VILO MasterMix was mixed with nuclease-free water. The master mix 
was added to the denatured mixture. Additionally, a negative control was needed.  
 
Component RT reaction no RT reaction 
RNA sample from previous step 10µL 10µL 
SuperScript IV VILO Master Mix 4µL - 
SuperScript IV VILO No RT Control - 4µL 
Nuclease-free water 6µL 6µL 
Total volume 20µL 20µL 
 
Everything was mixed and placed into a PCR Cycler and following heating incubations 
were performed: 
 
Temperature Time 
25°C 10min 
50°C 10min 
85°C 5min 
 
 Afterwards, samples were cooled on ice or stored at -20°C until further use. 
2.7.6.2 qPCR by QuantStudio 7 Flex Real Time PCR System 
After genomic DNA digestion and cDNA synthesis, the TaqMan qPCR mixture was 
prepared: 
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Components qPCR reaction Negative control 
cDNA 5µL - 
nuclease-free water 4µL 9µL 
TaqMan Fast Universal PCR Master Mix 
(NoAmpErase UNG) 
10µL 10µL 
Assay Probe 1µL 1µL 
Total volume 20µL 20µL 
Each qPCR reaction was pipetted into 2-3 wells of a 96-well MicroAmp EnduraPlate to 
have technical duplicates or triplicates. The plate was placed into the QuantStudio 7 
Flex Real Time PCR System and run under fast conditions. The following program was 
run: 
Steps Temperature Time 
Initial step 95°C 20sec 
40 cycles: 
Denaturation 95°C 1sec 
Annealing and extension 60°C 20sec 
 
2.7.7 cDNA preparation and qPCR by Biomark HD  
The following steps were performed by Joseph Tamm, Foundational Neuroscience 
Center, AbbVie. 
2.7.7.1 Quantification of RNA samples 
cDNA was prepared as already described in chapter 2.8.4 “DNA digestion with 
RapidOut DNA Removal Kit with subsequent cDNA transcription by Transcriptor First 
Strand cDNA Synthesis”. cDNA samples were incubated at 65°C to degrade any 
present RNA and subsequently, RNA concentration was measured using the Quant-iT 
OliGreen ssDNA Kit: 
Samples were mixed with the aqueous working solution, incubated 2-5min at room 
temperature and fluorescence was measured. By the help of a standard curve, the 
RNA concentration was determined. Samples were diluted to 20ng/µL. 
Subsequently, a preamplification step is performed. 
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2.7.7.2 Preamplification step 
Samples were preamplified by using the TaqMan PreAmp Master Mix:  
 
Component Volume per reaction Final concentration 
TaqMan PreAmp Master Mix 
(2x) 
2.5µL 1x 
Pooled assay mix (0.2x, each 
assay)  
1.25µL 0.05x (each assay) 
cDNA sample 1.25µL 0.02-5ng/µL 
Total volume 5µL - 
 
The pooled assay mix consists of all primer pairs needed for later qPCR and is already 
premixed by the supplier. 
Preamplification is performed by the following schedule: 
Step Temperature Time Cycles 
Enzyme activation 95°C 10min Hold 
Denature 95°C 15sec 13 cycles 
Anneal/Extend 60°C 4min 
Enzyme 
inactivation 
99°C 10min Hold 
Final 4°C ∞ Hold 
 
After preamplification, the 5µL sample is diluted in 50µL of water and a small part is 
used for qPCR sample preparation. 
2.7.7.3 qPCR sample preparation 
For qPCR, sample premix master mix was prepared: 
Component Volume 
TaqMan Fast Advanced 
Master mix 2x 
444µL 
Sample loading reagent 
20x 
44.4µL 
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Then, qPCR reactions were prepared. 
 
Component Volume for 1 reaction 
Sample premix 4µL 
Preamplified cDNA products diluted 1:10 3.27µL 
Total PCR reaction mix volume 7.27µL 
 
 
The Fluidigm 96.96 IFC was placed into the Juno for priming for 21min. Afterwards, 
5µL of each TaqMan assay was pipetted into the assay inlets of the Fluidigm 96.96 
IFC, which consists of TaqMan 20x qPCR assays and 2x assay loading reagent.  
Samples were loaded into the Fluidigm 96.96 IFC sample inlets. Juno mixed the 
assays with the samples and the plate was placed into Biomark HD, where qPCR takes 
place. Cycling times were performed as shown in the table: 
Steps Temperature Time 
Thermal mixing 70°C 40min 
Initial step 60°C 30sec 
Denaturation 98°C 60sec 
35 cycles: 
Denaturation 97°C 5sec 
Annealing and extension 60°C 20sec 
 
2.7.8 Data analysis of qPCR results 
For relative quantification, CT values of RNA samples were analyzed by the 2-(ΔΔ-CT)-
method: CT-values of the samples were normalized to the CT values of 2-3 
housekeeping genes of the same sample as indicated, and then normalized to D0 
samples. Afterwards, fold change was calculated.  
In case that CT-values were undetected, they were set to the max of cycle number, 
means CT=40 or in case of the Biomark HD qPCR, they were set to 28. If enough 
replicates were present, statistical analysis could be performed. 
2.7.9 Statistical analysis for qPCR 
For statistical analysis, GraphPad Prism Version 7 was used. 
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2.7.9.1 One-way ANOVA with multiple comparisons 
In the case that various conditions needed to be compared for a time point, one-way 
ANOVA was used if the data were normally distributed. 
To compare the means among the different conditions, multiple comparisons analysis 
was used. In that regard, Tukeys correction was applied which takes into consideration 
the scattering of the data, leading to a more precise result.  
2.7.9.2 Unpaired t-test and Welch’s t-test 
When two conditions were compared with each other, the samples were tested for 
normal distribution by Shapiro-Wilk test. 
In case of equal variances, an unpaired t-test was performed. If variances were 
different, a Welch’s t-test was performed. 
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3 RESULTS 
3.1 Implementation of xeno-free hiPSC-culture conditions 
3.1.1 The xeno-free coating agent LN521 is suitable for hiPSC-culture 
To establish a xeno-free cell culture system, the conventional culture conditions were 
examined thoroughly and ingredients deriving of animal-origin were identified and 
replaced by xeno-free versions. 
In hiPSC-culture, various culture media can be used, such as mTeSR, StemFlex and 
E8 medium. In order to start with a xeno-free hiPSC-culture, E8flex medium was used 
which is already a xeno-free medium (Chen et al., 2011). This medium consists of only 
8 necessary ingredients for hiPSC culture, described by Chen et al. (Chen et al., 2011). 
During neural induction conventional culture conditions use a combination of media 
and supplements. Frequently, a mixture of Neurobasal medium supplemented with 
B27 supplement (without vitamin A) and DMEM/F12 medium with N2 supplement, is 
used (Shi et al., 2012a). During induction, several pathway modulators are used to 
influence the cells towards differentiation into the neuroectoderm. These modulators 
are either small molecules or recombinant proteins. In this regard, rather small 
molecules were used for better stability and robustness of differentiation. 
In later stages, cells need to be expanded. In this regard, the same basal medium can 
be used, but different pathway modulators are needed, for instance the growth factor 
basic fibroblast growth factor (FGF) (Elkabetz et al., 2008; Falk et al., 2012; Shi et al., 
2012a; Yao et al., 2006; Zhang et al., 2001).  
After expansion, cells need to be finally matured into neurons. Here again, different 
pathway modulators are beneficial for success, for instance brain-derived neurotrophic 
factor (BDNF) and glial-derived neurotrophic factor (GDNF), which are neurotrophic 
factors that promote neuron maturation and survival (Love et al., 2005; Vicario-Abejon 
et al., 1998).  
In this regard, the proteins needed during differentiation, were switched to recombinant 
proteins manufactured in an animal-free manner. In this setting, these proteins were 
FGF, BDNF and GDNF. Further, the carrier protein needed for preparation of these 
proteins was switched from bovine serum albumin (BSA) to human serum albumin 
(HSA).  
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Two other main ingredients of animal origin found in culture media and components 
were the coating agent Matrigel and BSA, which is found in cell culture media as well 
as in protein solutions as carrier proteins as mentioned before. Matrigel is an 
extracellular matrix isolated from Engelbreth-Holm-Swarm mouse sarcoma (Kibbey, 
1994). A xeno-free alternative for Matrigel represent human recombinant extracellular 
matrix proteins, such as vitronectin (VTN) or laminins (Badenes et al., 2016; Laperle 
et al., 2015; Yasuda et al., 2018). Here, VTN-N and laminin-521 (LN521) coatings were 
tested with three hiPSC lines (hiPSC_1-3). For both coatings, cells could attach to the 
cell culture dish (Figure 11A). In the end, LN521 was picked as the general coating 
component. Majority of cells seeded onto LN521-coated dishes could already attach 
within 4 hours compared to VTN-N-coated dishes, in which only a part of the cells was 
visibly attached at that moment (Figure 11B). When checking hiPSC_1 on LN521 
coating, the pluripotency marker OCT4 was still expressed homogeneously on protein 
level after 5 passages, indicating that LN521 does not have negative effects on 
pluripotency (Figure 11C). The findings led to the conclusion that LN521 is a xeno-free 
alternative for Matrigel as hiPSCs adhere very quickly to LN521 compared to VTN-N 
and LN521 does not affect pluripotency of hiPSCs.   
 
Figure 18: Various hiPSC lines adhere and grow not only on Matrigel but also on xeno-free 
alternatives. 
A: Phase contrast images of hiPSC_1 and 2, which were grown on Matrigel, vitronectin (VTN-N) and laminin-
521 (LN521). hiPSC_3 was grown on VTN-N and LN521 only. Cells attached to and grew on all three coating 
agents. Scale bar: 100µm. 
B: Phase contrast images of hiPSC_1 and 2 after 4 hours of seeding. Cells were seeded at the same time in 
same densities on VTN-N and LN521. For LN521 coating, more cells attached within 4 hours compared to 
VTN-N. Scale bar: 100µm.  
C: Immunofluorescence staining of hiPSC_1 grown on LN521. Cells were stained for Hoechst and the 
pluripotency marker OCT4. Cells were highly positive for OCT4. Scale bar: 100µm. 
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3.1.2 A gradual change from E6 medium towards Basal Medium containing xeno-free 
B27 supplement is suitable for neural induction 
In a next step, Basal Medium (BM), which is usually used in the course of 
differentiation, was switched initially to the fully defined E6 medium. This medium is 
the direct equivalent of E8 medium, but without the pluripotency-supporting growth 
factors FGF and TGF-β (Chen et al., 2011). Due to a low protein content of E6 medium, 
cells did not survive when E6 medium supplemented with several pathway inhibitors 
 
Figure 20: hiPSCs benefit from induction conditions when switching gradually from the protein-poor 
medium E6 towards the protein-rich medium, here called Basal Medium (BM) after 2 days of 
induction. 
A: hiPSC_1 was induced by inhibition of BMP, MEK and WNT pathways in E6 medium alone or in E6 medium 
with gradual transfer to BM. When cells were induced in the protein-poor E6 medium alone, most of the cells 
detaches at D5. When switching gradually towards a protein-rich medium, here BM, cells were alive and looked 
unaffected. Scale bar: 100µm. 
B: Optimized induction scheme for neural induction. E6 medium with small molecules is used until day 2. Then, 
a 50:50 medium mixture of E6 and BM is used for the cells with same concentrations of small molecules. At 
day 3, the medium consists of 100% of BM. 
D: day, E8flex: E8flex medium, ROCK-i: Y-27632 (also known as ROCK inhibitor), E6: E6 medium, BM: Basal 
Medium. 
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was used for a longer treatment than for 4 days (Figure 12). As E6 medium is a very 
“poor” medium compared to BM, which contains high concentrations of BSA/HSA, the 
small molecules supplemented in the E6, needed for pathway modulation, possibly 
reached a higher efficient concentration as they cannot be masked by the missing 
serum albumin in the medium. This higher effective concentration of small molecules 
probably reached a threshold that was toxic for the cells. Qi and colleagues also 
observed this phenomenon and therefore suggested to alternatively titrate the 
concentrations of small molecules (Qi et al., 2017). In this regard it was found that 
 
Figure 22: B27 supplement without vitamin A can be replaced by xeno-free CTS-B27 supplement with 
vitamin A. 
hiPSC_1 was differentiated by inhibition of BMP, MEK and WNT pathways in media either containing B27 
without vitamin A or CTS B27 with vitamin A. 
A: Phase contrast images of hiPSC_1 after 6 days of induction. Cell layers appear comparable when induced 
by both media containing B27 supplement without vitamin A and CTS B27 supplement with vitamin A. Scale 
bar: 100µm. 
B: qPCR analysis for PAX6 and FOXG1. Data were normalized to the housekeeping genes ACTB, B2M and 
GAPDH. Samples were normalized to the average of D0 and set to 1 as starting point at D0. Both conditions 
show fold similar increase for both PAX6 and FOXG1, a cleft between conditions is visible, which remains the 
same over the time course. B27 w/o vit. A: n = 8, CTS B27 with vit. A: n = 2, error bars: SEM. 
C: Immunofluorescence staining of induced cells after 6 days of induction. Cells were stained for the 
neuroectoderm marker PAX6. Cells express PAX6 and stainings from both conditions show comparable 
staining pattern. Scale bar: 100µm. 
D: Immunofluorescence staining of hiPSC_1 after 6 days of induction. Cells were stained for the markers SOX2, 
OTX2 and PAX6. Cells are positive for all three markers. Both conditions show similar staining pattern. Scale 
bar: 100µm. 
E: Immunofluorescence staining of hiPSC_1 after 6 days of induction. Cells were stained for the markers 
FOXG1 and SOX1. Cells are positive for FOXG1 and majority of cells is also positive for SOX1. Staining 
patterns look comparable for both B27 supplements, for FOXG1, the staining is slightly stronger for CTS B27 
supplement with vitamin A. Scale bar: 100µm. 
Results 
56 
 
gradual switch from E6 medium to BM eliminated the need to titrate all the small 
molecules (Figure 12A and B).  
For neural inductions, B27 supplement without vitamin A (without retinoids) was 
replaced by CTS-B27 with vitamin A. CTS is a product line which stands for cell therapy 
systems. Products are manufactured with very high certified standards and can 
therefore be even used for therapeutic approaches. At the time of experiments, no 
CTS-B27 without vitamin A was available. This could have been used for more 
consistency with regards to vitamin A. Opposite opinions exist on the effect of vitamin A 
during neural induction for forebrain progenitors: Some groups claim it has adverse 
effects on neural induction and therefore, do not use it (Kirkeby et al., 2012; Li et al., 
2009), other groups use it and still derive cortical neurons (Espuny-Camacho et al., 
2013; Kirwan et al., 2015; Shi et al., 2012b). 
When comparing B27 w/o vitamin A to CTS-B27 with vitamin A, there was no obvious 
morphological difference between the cells (Figure 13A). Therefore, it was concluded 
that B27 supplement without vitamin A can be replaced by the xeno-free version CTS-
B27 containing vitamin A and that vitamin A does not appear to have an effect in this 
differentiation setting. This might be due to two reasons: 
On one hand, vitamin A simply does not have an effect during neural induction. Or 
vitamin A is not exposed long enough or in high enough concentrations during the 
whole induction: B27 supplement is included in BM only and not in the E6 medium. 
Therefore, vitamin A is present from day onwards in lower concentrations and it is only 
present fully from day 3 onwards. Further, vitamin A is only present in traces in the B27 
supplements. Immunofluorescence stainings for several markers also showed great 
similarity between both B27 supplements (Figures 13C-E). For FOXG1 staining, the 
cells showed potentially stronger signal when using CTS-B27 supplement 
(Figure 13E). 
On RNA level, both B27 supplements led to a similar increase for the neuroectoderm 
marker PAX6 at D3 and D6 respectively (Figure 13B). However, CT values for the 
experiments with the different B27 supplements already varied at D0, which might 
contribute to the cleft at subsequent time points (Figure 13B). 
 
To summarize, gradual switch from E6 medium towards BM was suitable for neural 
induction, especially when titrating small molecules wants to be avoided. Further, the 
CTS-B27 supplement represents a xeno-free alternative for the conventionally used 
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B27 supplement: There is no obvious effect of the vitamin A on neural induction in this 
setting and the xeno-free version of the supplement also did not have an adverse 
effect.   
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3.2 Optimization of a xeno-free and chemically defined differentiation protocol 
3.2.1 MEK inhibition accelerates neural induction in hiPSCs 
In previous protocols, neural induction in hiPSCs takes around 12 days (Kirwan et al., 
2015; Shi et al., 2012a). Therefore, the aim was to identify manipulations of the protocol 
to accelerate the process of neural induction. In their publication Greber and 
colleagues described that inhibition of the MEK pathway, which is responsible for FGF 
signal integration, could accelerate neural induction and within two weeks, they could 
even generate sensory neurons derived from hiPSCs (Greber et al. 2012). 
To test the accelerating effect of MEK inhibition for neural induction, inhibitors of BMP 
and TGF-β, commonly called double SMAD inhibition (termed here as “dSMADi”) were 
compared with dSMADi containing additionally a MEK inhibitor. Immunofluorescence 
stainings indicated that after 6 days of induction cells expressed strong nuclear PAX6 
protein in the condition with MEK inhibition compared to dSMADi, in which PAX6 
expression was still very weak (Figure 14 A). Interestingly, when leaving out the TGF-β 
inhibitor, stainings looked comparable, indicating that TGF-β inhibitor was not 
necessary in our induction setting (Figure 14A). 
On mRNA level, all three induction conditions led to a 100 to 1000-fold decrease of the 
pluripotency marker OCT4 during differentiation (Figure 14B). MEK inhibition led to an 
increase of PAX6 expression, which reached a plateau at D5 with an approximate 
6500-fold upregulation compared to D0 (Figure 14B). In comparison, dSMADi showed 
only an approximately 650-fold upregulation from D4 onwards, indicating an 
approximately 10-fold lower increase in expression on mRNA level compared to the 
other two conditions containing MEK inhibition (Figure 14B).  
For FOXG1, the upregulation was the slowest for dSMADi reaching the same level of 
the other two conditions at D6, whereas the other conditions had a stronger 
upregulation from day 2 onwards and reached a plateau already at day 3 or 4 during 
induction (Figure 14B). 
For PAX6 a significant difference between the dSMADi condition compared to the other 
two conditions was seen from days 2 to 6. P-values were ranging between 0.0017 at 
day 6 and 0.0483 at day 4 for comparisons of dSMADi to the double inhibition of BMP 
and MEK pathways. The two other conditions, inhibitions of BMP, TGF-β and MEK 
pathways and inhibitions of BMP and MEK pathways only, did not show any 
differences, indicating both conditions worked comparably. Significant differences 
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between dSMADi and the triple inhibition BMP, TGF-β and MEK pathways were 
detected for all days except for day 5. 
Statistical analysis for FOXG1 did not show any differences between the conditions 
except at D4 a significant difference between dSMADi and the condition in which BMP 
and MEK pathways were inhibited was detected. However, a trend was observed, 
similar to PAX6, that dSMADi was slower upregulating FOXG1 (Figure 14B). It is 
possible that with larger sample size, a statistically significant difference might be 
detected. 
In this setting it was found out that when leaving out the TGF-β inhibitor (inhibiting BMP 
and MEK pathways only), neural induction took place in the same speed as in the 
condition with additional inhibition of the TGF-β pathway, indicating no beneficial effect 
of the TGF-β inhibitor in this experimental setting (Figure 14B). 
In conclusion, the experiments confirmed that MEK inhibition accelerated neural 
induction and that at least BMP inhibition was needed for neural induction. 
 
Figure 24: MEK inhibition accelerates neural induction. 
Cells were induced by either inhibition of TGF-β and BMP pathways (dSMADi), or by inhibition of TGF-β, BMP 
and MEK pathways, or by inhibition of BMP and MEK pathways alone. 
A: Immunofluorescence stainings of the cells at D0 and D6 of induction. Cells were stained for the 
neuroectodermal marker PAX6. Cells induced by conditions containing MEK inhibition showed greater PAX6 
staining compared to dSMADi. Scale bar: 100µm. 
B: qPCR analysis of the pluripotency gene OCT4, the neuroectodermal marker PAX6 and the forebrain marker 
FOXG1. Data were normalized to housekeeping genes GAPDH, RPL13 and UBC and then to D0. Samples of 
each time point were tested for normal distribution by Shapiro-Wilk-test. Except at D1 for PAX6, data were 
normally distributed. For these samples, a one-way ANOVA test was performed with Tukey’s multiple 
comparison. Conditions containing MEK inhibitor quicker upregulated PAX6 and FOXG1 mRNA. For PAX6 
mRNA, dSMADi was significantly different from the other two conditions, except at D5: Here, only dSMADi 
differed from inhibition of BMP and MEK pathways. Conditions containing MEK inhibition were not significantly 
different from each other. For FOXG1 no significant difference was found among the conditions, except at D4, 
dSMADi was significantly different from inhibition of BMP and MEK pathways. n=3, error bars: SEM. qPCR was 
performed by Joseph Tamm, FNC.  
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3.2.2 hiPSC lines may be susceptible towards neural crest differentiation 
To see whether BMP and MEK inhibition alone were robust and reproducible, three 
hiPSC lines from healthy but different donors (named here “hiPSC_1, 2, 3”, 
respectively) were induced by this condition.  
From D6 onwards, first differences on morphological level could be observed for 
hiPSC_1 compared to the other two lines (Figure 15A): hiPSC_2 and 3 formed neural 
rosettes within 6 days of induction, whereas some cells of hiPSC_1 started to form 
spheroid structures on top of the homogeneous cell layer (Figure 15A, red arrows: 
sphere formation, green arrows: examples for rosette structures). As a possible 
explanation, it was assumed that these spheres might be cells of neural crest origin as 
it was described that they form separately of CNS progeny (Munst et al., 2018). In 
neural development, formation of neural crest is mainly dependent on WNT signaling 
(Blauwkamp et al., 2012; Moya et al., 2014; Tchieu et al., 2017). Therefore, in a next 
experiment, cells were treated by inhibition of BMP, MEK and an inhibitor of general 
WNT signaling (termed here as “WNTi”), IWP2. IWP2 inhibits WNT secretion in cells, 
thus blocking both canonical and non-canonical WNT signaling that is endogenously 
produced by the cells (Chen et al., 2009). After 6 days, hiPSC_1 culture morphology 
looked the same as the other two hiPSC lines (Figure 15A). To further validate this 
 
Figure 26: Neural induction by MEK- and BMP inhibition leads to different morphologies among 
hiPSC lines derived from various donors. 
hiPSC_1 - 3 were seeded for induction and induced for one week.  
A: Phase contrast images at D0 and D6 of induction. When inhibiting BMP and MEK pathways only, hiPSC_1 
shows sphere formation indicated by red arrows, whereas the other hiPSC lines form a neuroectodermal layer 
with rosette morphology indicated by green arrows. When inhibiting with general WNT signaling additionally, 
cell morphology of hiPSC_1 can be rescued. 
Red arrows: sphere formation, green arrows: rosette formation 
B: Immunofluorescence staining of hiPSC_1 at D6 of induction. Cells were stained for the neuroectodermal 
marker PAX6 and the neural crest marker SOX10. Patches of cells are SOX10+ when inhibiting BMP and MEK 
pathways only, but probably, they are PAX6-. The SOX10+ patches resemble the spheres in the phase contrast 
images. Scale bar: 100µm. 
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hypothesis, immunofluorescence analysis was used. When comparing both conditions 
by immunofluorescence staining, the spheroid structures stained positive for the neural 
crest marker SOX10, but weakly for the CNS marker PAX6. When cells were treated 
with the additional general WNT inhibitor, no SOX10+ cells could be detected by 
immunofluorescence staining anymore (Figure 15B).  
For mRNA analysis all three lines were considered as biological replicates 
(Figure 16A).  
Both conditions led to a similar fold decrease for OCT4, indicating the exit of the cells 
from the pluripotent state (Figure 16A). Both conditions led to a strong increase in 
expression of the neuroectoderm marker PAX6 by several orders of magnitude 
(Figure 16A). It appeared that BMP and MEK inhibition alone could lead to an even 
higher increase of PAX6 mRNA. Some further differences could be observed for the 
forebrain marker FOXG1 and the neural crest marker SOX10 (Figure 16A): When 
inhibiting BMP and MEK pathways in the cells, FOXG1 fold change increased up to 
550-fold until day 3, and then subsequently fold increase dropped to 20 compared to 
inhibition of BMP, MEK and general WNT pathways, in which FOXG1 fold change was 
increasing up to 230-fold at day 3 and 400-fold through day 6 (Figure 16A). When 
comparing SOX10 fold change, both conditions led to a 15 or 10-fold increase until day 
3, but then for inhibition of BMP and MEK pathways, the fold change increased further 
up to 60, whereas for inhibition of BMP, MEK and general WNT pathways, a plateau 
was reached (Figure 16A). 
 
When regarding all lines individually for FOXG1 and SOX10, the behavior of the cells 
during time and condition was mostly similar. Differences could be seen among the 
different conditions which reflect the differences in Figure 6A: Inhibition of BMP and 
MEK pathways led to a decrease of FOXG1 from D3 onwards and rather a progressive 
increase of SOX10, whereas for the condition with additional WNT inhibition, FOXG1 
and SOX10 increased until D3 reaching a plateau (Figure 16B). 
 
Results 
62 
 
 In summary, it was found out that some hiPSC lines seem to be prone for neural crest 
 
Figure 28: Lack of WNT inhibition leads to a greater variability of data and a tendency for neural crest 
formation on RNA level. 
A: qPCR analysis of the genes OCT4, PAX6, FOXG1 and SOX10. The data of the three hiPSC lines 1-3 were 
considered as biological triplicates, therefore n=3. Data was normalized to the three housekeeping genes ACTB, 
B2M and GAPDH. Further, data of each induction condition was normalized to the mean of D0 of all three lines 
for the respective condition. Some main differences in fold change are seen for FOXG1 and SOX10. BMP and 
MEK inhibition are in favor of neural crest formation. n=1. Error bars: SEM, * = 0.0141, ** = 0.0029 
B: qPCR analysis of the genes FOXG1 and SOX10. The data from Figure A was deconvoluted and all three 
lines hiPSC1-3 were graphed. The fold change tendencies are roughly similar between the hiPSC lines and the 
indicated conditions.  
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formation during neural induction. Here, hiPSC_1 was forming SOX10+ spheres when 
no general WNT inhibitor was applied. This condition also led to an upregulation of 
SOX10 mRNA in the cells and faster downregulation of the forebrain marker FOXG1. 
Further, when inhibiting BMP and MEK pathways only, a greater variability of the data 
was seen when compared to the condition with additional general WNT inhibition.  
 
The reason for all the differences can be attributed to endogenous WNT signaling in 
the cells. This is consistent with descriptions in a review of Ortmann and Vallier 
(Ortmann and Vallier, 2017). They described that WNT signaling might vary among 
pluripotent stem cell lines and that WNT signaling can also be dynamic, concluding 
that WNT activity and expression might change from time to time. The expression of 
the three different WNT molecules WNT1, WNT3 and WNT3A was analyzed in the 
context of inhibition of BMP and MEK inhibition in the three hiPSC lines hiPSC_1-3.  
The expression between the three hiPSC lines for each of the WNTs at D0 was 
comparable. However, the fold increase during differentiation varied among the WNTs 
and among hiPSC lines: hiPSC_1, which also showed the strongest propensity to form 
neural crest, showed the highest upregulation of WNT1 (50 000 fold at D3, 34 000 at 
D6) and WNT3A (200 to 560-fold) compared to the two other lines, which showed a 
lower upregulation. This might be the reason why hiPSC_1 forms neural crest spheres 
when inhibited by BMP and MEK inhibitors only. 
As hiPSC_1 was the only cell line showing neural crest development, WNT fold 
changes were observed in this cell line under inhibition of BMP and MEK pathways 
and under inhibition of BMP, MEK and additional general WNT pathways. Not much 
difference was observed for WNT3 compared to the other WNTs. Expression of WNT3 
was already low throughout induction, but a 3-fold higher upregulation was observed 
in the case BMP and MEK inhibition was used compared to the condition with 
additional WNT inhibition (Figure 7B). Further, the highest upregulation was observed 
for WNT1: Approximately a 30 000-fold upregulation was observed when inhibiting 
BMP and MEK pathways only. When using additionally general WNT inhibition, an 
upregulation of only 12 000-fold was observed on mRNA level, with a tendency to 
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decrease in further time course (Figure 17B).  The difference lied between 3 to 10-fold 
 
Figure 30: Different hiPSC lines differ in expression and upregulation of WNT mRNA and inhibition of 
general WNT signaling leads to a feedback look in hiPSC_1. 
A: qPCR analysis of the genes WNT1, WNT3 and WNT3A of hiPSC_1-3 during induction by inhibition of BMP 
and MEK pathways. Data was normalized to the three housekeeping genes ACTB, B2M and GAPDH and to 
averaged D0 of all cell lines. Different upregulation of various WNTs is observed among the different 
hiPSC lines. n=1. 
B: qPCR analysis of the genes WNT1, WNT3 and WNT3A for hiPSC_1 during both induction conditions by 
either inhibition of BMP and MEK pathways or by inhibition of BMP, MEK and general WNT pathways. Data 
was first normalized to the three housekeeping genes ACTB, B2M and GAPDH and then to D0. When inhibiting 
general WNT during induction, fold increase for the different WNTs is smaller. n=1. 
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differences between the two conditions on mRNA level. 
For WNT3A, the fold change increased to roughly 10-fold at day 3, and further 
increased up to 300-fold when no WNT inhibitor was used during neural induction 
(Figure 17B). When WNT inhibitor was applied, the fold increase only reached 9 to 4-
fold at days 3 and 6 respectively (Figure 17B). 
The data indicated that WNT transcription on RNA level seemed to be reduced when 
general WNT signaling was inhibited, indicating a possible feedback-loop in the 
cultures (Figure 17B). WNT1 and WNT3A seemed to have a greater influence than 
WNT3 as greater fold increases were observed (Figure 17A and B). 
In conclusion, the application of a general WNT inhibitor could avoid neural crest 
formation in this setting by inducing a feedback-loop on WNT1 and WNT3A on RNA 
level. The application of general WNT inhibition led to a more robust condition as the 
variable endogenous WNT signaling was shut down in the cells, leading to a more 
comparable differentiation behavior in different pluripotent stem cell lines. 
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3.2.3 Inhibition of canonical WNT signaling is not sufficient to block neural crest 
formation 
As WNT signaling was identified as driver for neural crest differentiation, two pathways 
could be responsible: Non-canonical and/or canonical WNT signaling. 
To assess these possibilities, differentiation in hiPSC_1 was induced by inhibition of 
BMP-, MEK- and general WNT pathways by IWP2, or by inhibition of BMP-, MEK- and 
canonical WNT pathways only by XAV939 (XAV). XAV is a tankyrase inhibitor and 
therefore, induces degradation of β-catenin, leading to inhibition of the canonical WNT 
pathway. To further clarify the role of WNT signaling, differentiation in hiPSCs was also 
induced by inhibition of BMP-, MEK- and general WNT pathways with additional 
canonical WNT activation by 0.5µM of CHIR99021 (CHIR). This should lead to 
inhibition of any endogenous WNT signaling in the cells while specifically activating the 
canonical WNT signaling axis via GSK3-β. CHIR is an inhibitor of GSK3-β which leads 
to β-catenin signaling, therefore activating canonical WNT signaling. The low 
concentration of CHIR was chosen to achieve a slight dorsalization of the cell identity 
without reaching neural crest formation (Chambers et al., 2012). Higher 
 
Figure 32: Non-canonical WNT signaling is responsible for neural crest formation. 
hiPSC line1 was treated with inhibitors of BMP and MEK pathways and either with a general WNT inhibitor 
(IWP2), a canonical WNT inhibitor (XAV) or a general WNT inhibitor (IWP2) with slight simultaneous canonical 
WNT activation (0.5µM CHIR). 
A: Phase contrast images of the cells at D0, D7 and D10 of induction. Sphere formation can be seen when 
canonical WNT is inhibited alone without any other WNT inhibition. Red arrows indicate sphere formation. 
B: Immunofluorescence staining of cells at D6 of induction. Cells were stained for the neuroectodermal marker 
PAX6 and the neural crest marker SOX10. SOX10+ patches can be seen when canonical WNT is inhibited 
alone without any other WNT inhibition. Some single SOX10+ cells can also be found when general WNT is 
inhibited and cells are treated with the canonical WNT activator CHIR. The images indicate that non-canonical 
WNT signaling has a greater influence on neural crest formation compared to canonical WNT signaling. Scale 
bar: 100µM. 
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of FOXG1 from D3 onwards, indicating a caudalization of the cells in the later days of 
the differentiation process (Figure 19). 
Contrary to the expectations that WNT signaling leads to dorsalization of forebrain 
progenitors or even neural crest formation, canonical WNT activation led only to a slight 
upregulation of FOXG1 and SOX10 compared to the other conditions (Figure 19).  
 
This experiment indicated that neural crest formation was potentially induced by 
endogenous non-canonical WNT signaling pathway components of the cells which was 
not inhibited by XAV treatment. Canonical WNT signaling only seemed to be a minor 
activator of neural crest in the used conditions as seen on the immunofluorescence 
stainings (Figure 18B). Further, non-canonical WNT signaling seemed to have a 
caudalizing effect as OTX2 was upregulated whereas FOXG1 was being 
downregulated (Figure 19). 
 
To further clarify the role of WNT signaling, additional conditions were tested in 
hiPSC_1: 
1) Inhibition of BMP and MEK pathways as control for neural crest prone 
lines 
2) Inhibition of BMP, MEK and general WNT pathways by IWP2 
3) Inhibition of BMP, MEK and canonical WNT inhibition by XAV to see the 
effect of non-canonical endogenous WNT signaling if present 
4) Inhibition of BMP and MEK pathways plus canonical WNT activation by 
high (3µM) CHIR concentrations 
5) Inhibition of BMP, MEK and general WNT pathways plus slight canonical 
WNT activation by IWP2 and 0.5µM CHIR respectively to see the effect of slight 
canonical WNT activity with other WNT signaling blocked 
6) Inhibition of BMP, MEK and general WNT pathways plus strong canonical 
WNT activation by IWP2 and CHIR respectively to see the effect of strong 
canonical WNT activity without any other WNT signaling 
7) Inhibition of BMP, MEK and general WNT pathways by IWP2 plus 
WNT3A signaling to see the effect of canonical WNT signaling as WNT3A is 
known to activate canonical WNT signaling in cells. 
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8) Inhibition of BMP, MEK and canonical WNT pathways by XAV plus 
WNT3A signaling to see if canonical WNT activation by WNT3A are inhibited by 
the canonical WNT inhibitor XAV. 
On phase contrast images, for some conditions sphere formation was observed 
(Figure 20). Sphere formation was seen for conditions 1), 3) and 8) when inhibiting 
BMP and MEK pathways only or when inhibiting additionally canonical WNT pathways 
 
Figure 36: Non-canonical WNT signaling induces sphere morphology on induced hiPSCs. 
Phase contrast images of hiPSC_1 at D0, 6 and 10 with the indicated conditions. Sphere formation is 
sometimes better visible at later time points than D6. Sphere formation is seen for inhibition of BMP and MEK 
pathways and for conditions in which canonical WNT inhibitor was used. 
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MEK and general WNT pathway at D6 with an upregulation of 20-fold (Figure 21). 
Therefore, this condition was considered as the most promising one when aiming for 
forebrain neurons.  
All the conditions led to downregulation of the pluripotency markers OCT4 and NANOG 
(Figure 21). 
 
Highest FOXG1 upregulation was observed for condition 2) by inhibition of BMP, MEK 
and general WNT pathways. Therefore, this condition was considered as the minimal 
essential condition needed for forebrain induction. 
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3.2.4 Induction conditions are reproducible in various hiPSC lines 
As the minimal induction condition was identified, namely inhibition of BMP, MEK and 
general WNT pathways, in a next attempt, this condition was tested in several different 
hiPSC lines: It was tested in the three control lines hiPSC_1 - 5, and in two hiPSC lines 
carrying either an AD mutation in the PSEN1 gene (hiPSC_PSEN1) or a mutation 
found in frontotemporal dementia in the MAPT gene (hiPSC_MAPT).  
 
Figure 40: Inhibition of BMP, MEK and general WNT is reproducible in various hiPSC lines. 
The five different lines hiPSC_1, hiPSC_4, hiPSC_5 and the two disease lines hiPSC_MAPT and hiPSC_PSEN 
were induced by inhibiting either BMP, MEK and general WNT or by inhibiting BMP, MEK, general WNT and 
SHH. Phase contrast images indicate comparable behavior among hiPSC lines and between induction 
conditions. Scale bar: 100µm. 
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All tested cell lines showed similar behavior on morphological level during neural 
 
Figure 42: Induction conditions are reproducible in several cell lines. 
qPCR analyses of various hiPSC lines for the genes PAX6, FOXG1 and SOX10 when inhibiting BMP MEK and 
general WNT signaling. Various cell lines show a similar trend.  
A: Reverse transcription was performed by Transcriptor First Strand cDNA Synthesis Kit.  
B: Reverse transcription for these two cell lines was performed by Superscript polymerase. Therefore, the data 
was shown separately. 
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induction (Figure 22). Further, the different lines showed similar tendency on RNA 
levels during neural induction (Figure 23): Inhibition of BMP, MEK and general WNT 
pathways led to an upregulation of PAX6 between 5800-fold and 37 000-fold at D6 
(Figure 23).  
For FOXG1, an upregulation between 140 and 900-fold was seen when BMP, MEK 
and WNT pathways were inhibited (Figure 23). For SOX10, an upregulation between 
2 and 20-fold was seen when BMP, MEK and WNT pathways were inhibited 
(Figure 23).  
 
In conclusion, the minimal induction condition by inhibition of BMP, MEK and WNT 
pathways was reproducible in 7 individual hiPSC lines from which 2 were lines bearing 
mutations for AD or tauopathy.  
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3.2.5  SHH inhibition does not affect neural induction and could be used in case of 
ventralization of the culture 
In a next attempt, the SHH inhibitor Cyclopamine was included during induction to 
determine a possible dorsalizing effect. 
 
On cell morphology, SHH did not have an adverse effect and after 6 days of induction 
with inhibitors of BMP, MEK, WNT and SHH, the cell layer shows rosette formation 
(Figure 24A). Further, immunofluorescence staining analyses also did not show any 
difference between both conditions. When looking on mRNA fold change no difference 
can be observed between the condition of inhibiting BMP, MEK and general WNT and 
the condition with additional SHH inhibitor (Figure 24B). An interesting marker in that 
regard is EMX2, which is a dorsal forebrain marker. A reason why no difference is 
 
Figure 44: SHH inhibition does not impair neural induction in hiPSCs. 
hiPSC_1 was induced by inhibiting BMP, MEK, WNT pathways and additionally, by inhibiting SHH pathway. 
A: Phase contrast images of hiPSC_1 at D0 and D6 of neural induction. Cell morphology looks alike between 
both conditions. Scale bar: 100µm.  
B: mRNA analyses of the neuroectoderm marker PAX6, the forebrain marker FOXG1, the dorsal forebrain 
marker EMX2 and the neural crest marker SOX10. Data were normalized to the housekeeping genes GAPDH, 
RPL13 and UBC. No difference is seen for the conditions, in which either BMP, MEK and WNT pathways were 
inhibited or additionally, when SHH was inhibited. n=3, error bars: SEM. qPCR was performed by Joseph 
Tamm, FNC. 
C: Immunofluorescence analyses of hiPSC_1 induced for 6 days by inhibition of inhibiting BMP, MEK, WNT 
pathways and additionally, by inhibiting SHH pathway. Differentiation pattern looks similar among both 
induction conditions. Scale bar: 100µm.  
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observed between both conditions might be that no SHH is being expressed and 
therefore, inhibition might not show any difference. 
 
Therefore, it was concluded that inhibition of SHH is not affecting neural induction, but 
is not yet needed in the differentiation process and that SHH inhibition might have 
beneficial effects later during the expansion phase of NPCs. 
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3.2.6 Various expansion conditions after neural induction lead to neuronal outcome 
in cells 
Once minimal induction conditions were identified, which were a combination of BMP, 
MEK and general WNT inhibition for 6 days, the next step towards neuronal 
differentiation is the expansion phase of the neural progenitor cells. 
Usually, expansion and at the same time consolidation of the CNS identity is performed 
by basic fibroblast growth factor (bFGF), also known as FGF2, exposure (Elkabetz et 
al., 2008; Falk et al., 2012; Shi et al., 2012a; Yao et al., 2006; Zhang et al., 2001).  
Therefore, bFGF (FGF) was used as an expansion condition, but also FGF and general 
WNT inhibition were evaluated to prevent influence of endogenous WNT signaling 
during that period. As cells are supposedly still very early in development when 
expansion starts, namely after 6 days of induction, general WNT inhibition could still 
help in this stage to avoid neural crest formation. 
In both expansion conditions the neural progenitors formed a distinct rosette layer, 
indicative of CNS identity (Figure 25A at D9). In both expansion conditions used 
neurons were differentiating in later stages (Figure 25A). In brief, after 4 days of 
expansion, cells were matured in maturation medium (MM). MM consists of basal 
medium with several ingredients that support neuronal survival, such as BDNF and 
GDNF, but also cAMP, vitamin C and LN521 to promote adhesion during the course 
of final differentiation (Lepski et al., 2013; May, 2012). In the beginning, MM was 
supplemented with DAPT, a γ-secretase inhibitor and a MEK inhibitor which supports 
the final maturation of neurons (Borghese et al., 2010). After 4 days, cells were replated 
into fresh dishes coated with PLO and LN521. As soon as the culture contained cells 
with neuronal morphology only, this was usually the case after 1-2 weeks of maturation, 
DAPT and the MEK inhibitors were excluded from the medium (Figure 25C). 
Neurons could also be generated when using not only hiPSC_1 but also in other hiPSC 
lines, for instance in hiPSC_4 and in the Alzheimer’s Disease line PSEN1 (Figure 35A). 
 
On RNA level, fold decreases were observed for PAX6 and SOX10 over expansion 
time (Figure 25B). Fold decrease for PAX6 was moderate as a decrease of only 10 to 
50-fold was observed and PAX6 was still strongly expressed, indicating that cells 
present were of neural progenitor identity (Figure 25B). The decrease of SOX10 was 
best when WNT inhibitor is included and probably indicates that the cells lose their 
ability of neural crest formation over time which was of benefit in this regard 
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(Figure 25B). FOXG1 expression was not strongly influenced by the tested conditions, 
 
Figure 46: Neurons can be generated from various induction and expansion conditions.  
Cells were induced for 6 days by either inhibition of BMP, MEK and general WNT or by inhibition of BMP, MEK, 
general WNT and SHH pathways. Then, cells were expanded for 4 days by treatment with FGF or by 
simultaneous treatment with FGF and inhibition of general WNT signaling. Subsequently, cells were matured. 
A: Phase contrast images of cells during the course of differentiation. Pictures were taken on D0. D6, D9 and 
D23 of differentiation. 
B : qPCR analyses of the genes PAX6, FOXG1 and SOX10 during expansion conditions. Data were normalized 
to housekeeping genes and to D0 of start of induction. n=1. 
C: Differentiation scheme from hiPSCs towards neurons. 
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indicating that the cells maintained a CNS forebrain identity. When maintained with 
additional WNT inhibition, neural crest propensity was potentially even decreased 
stronger (Figure 25B). This would be in line with the known roles of WNT signaling in 
development.  
 
In a next experiment, cells were induced by inhibition of the BMP, MEK and general 
WNT pathways for 6 days, and then expanded with either one of the three expansion 
 
Figure 48: FGF expansion alone leads to a lower yield of neurons and rather promotes generation of 
non-neuronal cell types. 
Cells were induced by inhibition of BMP, MEK and general WNT signaling and subsequently expanded as 
indicated: either by FGF treatment alone, or FGF treatment with general WNT. Afterwards cells were matured. 
Notice that when cells were expanded by FGF, less cells were visible, and some non-neuronal cells can be 
seen which have greater volume around the nucleus than neurons. 
A: Immunofluorescence staining of neurons at D25 of differentiation. Cells were stained for MAP2 and TBR1. 
Cells were positive for TBR1. Scale bar: 100µm. 
B: Immunofluorescence staining of neurons at D25 of differentiation. Cells were stained for FOXG1, MAP2 and 
SATB2. Cells were positive for FOXG1 but not SATB2. Scale bar: 100µm 
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conditions: FGF treatment only, FGF treatment with simultaneous general WNT 
inhibition or by FGF treatment with simultaneous inhibition of general WNT and SHH 
signaling. After 4 days of expansion, cells were matured as described (Figure 25C). 
The resulting neurons were used for characterization by immunofluorescence staining 
(Figure 26 and 27). Staining for cortical layer markers indicated that the majority of 
cells was of early cortical layer identity as the cells were positive for TBR1 (TBR1+, 
 
Figure 50: Glutamatergic and GABAergic neurons can be derived by all three expansion conditions. 
Cells were induced by inhibition of BMP, MEK and general WNT signaling and subsequently expanded as 
indicated: either by FGF treatment alone, or FGF treatment with general WNT inhibition. Afterwards cells were 
matured.  
 A: Immunofluorescence staining of neurons at D25 of differentiation. Cells were stained for the vesicular 
glutamate transporter vGLUT2 and the dendritic marker MAP2. Scale bar: 100µm. 
B: Immunofluorescence staining of neurons at D25 of differentiation. Cells were stained for the vesicular GABA 
transporter vGAT1 and the dendritic marker MAP2. Scale bar: 100µm. 
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Figure 27). Further, on immunofluorescence staining level, no difference was observed 
between expansion condition FGF with inhibitor of WNT pathways and with additional 
inhibition of SHH pathway (Figure 27). 
 
The resulting neurons from FGF expansions did not look as promising as the ones of 
the two other expansion conditions (Figures 26 and 27). In all immunofluorescence 
stainings it looked like the cells derived by the FGF treatment alone also generated a 
non-neuronal cell type as less cells were generated, some of which had a bigger cell 
volume around the nucleus compared to neurons (Figure 26 and 27). Therefore, the 
 
Figure 52: Structural characterization of hiPSC-derived neurons. 
hiPSC_4 and hiPSC_PSEN1 were differentiated towards neurons with two different expansion conditions, one 
with FGF treatment and general WNT inhibition, the other with FGF treatment, general WNT inhibition and SHH 
inhibition. 
Immunofluorescence stainings of the two lines and two different expansion conditions at D45 of differentiation. 
Cells were stained either for MAP2 and TUBB3 or MAP2, 3R tau and total tau. Cells are highly positive for all 
markers, a nice network formation can be seen in the stainings. The treatments do not show any differences 
between the expansion conditions. Note that hiPSC_4 was seeded in a lower density than hiPSC_PSEN1. 
Scale bars: 100µm. 
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assumption arised that some additional inhibitors might be necessary in the expansion 
conditions to prevent the differentiation of an unwanted cell type.  
Further, derived neurons were stained for glutamatergic and GABAergic markers 
(Figure 27). Both expansion conditions generated glutamatergic and GABAergic 
neurons (Figure 27). 
The differentiation protocol was also tested in the hiPSC lines hiPSC_4 and PSEN1. 
Characterization by immunofluorescence stainings indicated similar results as the 
stainings in hiPSC_1. These cells were characterized structurally by staining of 
cytoskeletal markers tubulin β3 (TUBB3) and tau (Figure 28). The cells showed 
network formation visible by TUBB3 staining and tau staining (Figure 28). The culture  
 
To summarize the findings from these experiments, the minimal induction condition, 
namely inhibition of BMP, MEK and general WNT pathways, was sufficient to generate 
neuronal outcome in the end. Conditions for the expansion and solidification of cortical 
NPC identity were evaluated: FGF only, FGF with simultaneous inhibition of general 
WNT pathways and FGF simultaneous inhibition of general WNT and SHH pathways. 
All expansion conditions were also suitable for deriving neurons. When evaluating 
mRNA data, expansion conditions with WNT inhibition had advantages in 
downregulation of neural crest marker SOX10. 
Therefore, it can be concluded to use further pathway inhibitors during expansion 
simultaneous to FGF treatment to avoid formation of any other cell types. WNT 
inhibition can further decrease neural crest formation. 
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3.2.7 A non-neuronal cell type overgrows the neuronal culture 
During individual differentiation attempts of the neuronal culture some non-neuronal 
cell types were visible also when expansion conditions were used, in which pathway 
inhibitors, such as WNT inhibition, were present. The longer the culture was grown, 
the more this cell type was overgrowing the neuronal culture (Figure 29), due to their 
proliferative nature compared to the postmitotic neurons. The cobblestone-like 
morphology was reminiscent of an epithelial cell type, such as keratinocytes. Indeed, 
upon immunofluorescence analysis, these cells could be identified as positive for 
cytokeratin18, further indicating such an identity. 
One possibility, how cytokeratin18+ cells might arise from this culture, was that 
differentiating hiPSCs developed into the wrong lineage. During neural induction, 
which is part of the ectodermal lineage, some cells might become for instance cells 
from neural crest, non-neural ectoderm, ect. (Tchieu et al., 2017). In this regard, 
besides SOX10 as neural crest marker, AP2α, which is a non-neural ectoderm marker, 
was an additional marker that appeared to be of interest. 
Further, effects that might influence neural crest formation or non-neural ectoderm 
formation were taken into consideration, such as cell density during neural induction 
(Chambers et al., 2009). 
Therefore, in an experiment, cells were seeded in the densities 62 500, 125 000, 
250 000, 500 000 and 750 000 cells/cm² and the next day, neural induction was started 
as outlined before. At the end of induction, cells were stained for cell lineage markers 
and RNA samples were collected for qPCR. 
 
Figure 54: A non-neuronal cell type overgrows the neuronal cell culture. 
hiPSC_1 was differentiated towards neurons. At some parts of the cell culture, non-neuronal looking cells were 
identified. Immunofluorescence staining of hiPSC_1-derived neurons. Cells were stained for cytokeratin18 and 
the dendritic marker MAP2. Some cells were positive for cytokeratin18. Scale bar: 100µm. 
 
Results 
84 
 
 Immunofluorescence staining analyses indicated greater AP2α expression in less 
 
Figure 56: Non-neural ectoderm formation is density-dependent. 
hiPSC_1 was seeded in various densities and induced by inhibition of BMP, MEK and general WNT signaling. 
Cells were seeded at different densities from 62 500cm² - 750 000cm² and induced for 6 days. 
A: Immunofluorescence staining of hiPSC_1 at D6 of induction. Cells were stained for the neuroectoderm 
marker PAX6, the neural crest marker SOX10 and the non-neural ectoderm marker AP2α. Scale bar: 100µM. 
B: qPCR analysis of the genes PAX6, FOXG1, SOX10 and AP2α. Data was normalized to the housekeeping 
genes ACTB and GAPDH and to an average of D0. The data shows proportionality of density towards SOX10 
marker expression and reciprocal proportionality of density and AP2a marker expression. n=1. 
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dense cultures compared to denser cultures (Figure 30A). RNA analyses indicated that  
 
Figure 58: Endogenous BMP signaling leads to expression of the non-neural ectoderm marker AP2α. 
hiPSC_1 was induced for 6 days by either inhibition of BMP, MEK and general WNT signaling, or by inhibition 
of MEK and general WNT signaling or by inhibition of TGF-β, MEK and general WNT signaling. 
A: Immunofluorescence staining of cells at D6 of induction. Cells were stained for the neuroectoderm marker 
PAX6, the neural crest marker SOX10 and the non-neural ectoderm marker AP2α.  
B: qPCR analysis of the genes PAX6, FOXG1, SOX10 and AP2α. Data was normalized to the housekeeping 
genes ACTB and GAPDH and to an average on D0. D0: n=2, BMP-i + MEK-i + general WNT-i: n=2, other 
conditions: n=1. 
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PAX6 and SOX10 expression was proportional to seeded cell density (Figure 30B). 
This was contradictory in the case of SOX10, which was described by Chambers to be 
reciprocally proportional to cell density (Chambers et al., 2009). 
Interestingly, AP2α seems to be reciprocally proportional to seeded cell density on 
immunofluorescence staining images as well as on RNA level (Figure 19A and B). 
Further, some cells appeared to be positive for PAX6 as well as AP2α.  
According to development (Tchieu et al., 2017; Wilson and Hemmati-Brivanlou, 1995), 
formation of non-neural ectoderm is dependent on BMP signaling. This is particularly 
interesting, as BMP inhibition is often used in neural induction (dSMADi, our 
conditions), but various BMP signaling inhibitors exist. To evaluate whether 
endogenous BMP signaling could still be responsible for AP2α+ cells, hiPSC_1 was 
induced by three different induction conditions: Inhibition of BMP, MEK and general 
WNT inhibitors, inhibition of BMP and MEK inhibitors only and inhibition of TGF-β, MEK 
and general WNT inhibitors. Indeed, cells that were not induced by using a BMP 
inhibitor formed AP2α+ cells (Figure 31A), indicating the definite need for such an 
inhibitor. This finding was also recapitulated on mRNA level: The conditions without 
BMP inhibitor showed a higher fold increase for AP2α/TFAP2 compared to the 
condition containing a BMP inhibitor (Figure 31B). 
In a subsequent experiment, the two BMP inhibitors Dorsomorphin (DM) and 
LDN193189 (LDN), which are structurally similar and are both ALK inhibitors, were 
compared with each other. In various publications, either one of both inhibitors was 
used (Chambers et al., 2012; Greber et al., 2011; Maroof et al., 2013; Qi et al., 2017; 
Shi et al., 2012b). Briefly, cells were induced as previously described by inhibiting BMP 
pathway either by 1µM of DM or 0.5µM of LDN, with additional inhibition of MEK and 
WNT pathways. Concentration of LDN was lower as potency is greater for this 
compound. BMP inhibition by DM could not complelety prevent formation of AP2α+ 
cells on immunofluorescence stainings, whereas LDN could completely prevent 
expression of AP2α in cells (Figure 32A).  
On RNA level, LDN showed some advantages compared to DM: Induction by LDN led 
to a quicker downregulation of OCT4, a higher fold increase for FOXG1, but a lower 
increase for SOX10 and AP2α compared to the induciton with DM (Figure 32B). 
 
The data led to the conclusion that LDN had greater efficiency in inhibiting BMP 
signaling compared to DM and should be preferred. 
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Figure 60: The BMP inhibitor LDN193189 is more beneficial than DM with regards to neural induction. 
hiPSC_1 was induced by inhibition of BMP, MEK and general WNT pathways. As BMP inhibitor, either 1µM 
DM or 0.5µM LDN was used. 
A: Immunofluorescence stainings were performed at D6 of induction. Cells were stained for the neuroectoderm 
marker PAX6, the neural crest marker SOX10 and the non-neural ectoderm marker AP2α. 
B: qPCR analysis of the genes NANOG, OCT4, PAX6, FOXG1, OTX2, SOX10 and AP2α. Data was normalized 
to the housekeeping genes ACTB and GAPDH and to D0 of the respective condition. n=1. 
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3.2.8 A freezable neural progenitor cell type is acquired in the established 
differentiation protocol 
A great benefit of a differentiation protocol is the possibility of deriving a freezable 
progenitor cell type. Getting hold of such a progenitor allows the generation of large, 
frozen cell banks which, once successfully characterized, can be used in less time for 
more reproducible results. 
Therefore, hiPSC_1 was differentiated as described until day 14 of differentiation 
(Figure 33A). At this time point, cells were being replated. A part of the cells was 
replated, whereas the other portion was frozen using a controlled rate freezing 
container and stored in liquid nitrogen temperatures. The frozen progenitors were 
thawed at a later time point. Cell viability during replating was at 95% for cells that were 
directly replated, compared to the thawed cells, in which viability of cells was only 74%. 
Nevertheless, one day after thawing, the progenitors already had a neuronal 
 
Figure 62: Neural progenitors can be frozen down and thawed again.  
A: Differentiation scheme of hiPSCs towards neurons. At D14, some cells were seeded, others were frozen for 
thawing in later stages. 
B: Phase contrast images of hiPSC_1 at D0, at D16 of differentiation and at D15, one day after thawing. Thawed 
cells have a similar neuronal morphology as neurons from a differentiation without a freezing step in between. 
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morphology, comparable to the progenitors that were replated directly without any 
freezing step.  
This experiment indicated that a freezable progenitor can be derived from this 
differentiation protocol. This would also allow to perform the generation of this 
progenitor in large batches, skipping the first 14 days of the protocol for repetitive 
experiments.  
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3.2.9 hiPSC-derived neurons become electrophysiologically active in a time-
dependent manner 
To determine whether the forming neurons are functionally active, neuronal 
progenitors were replated onto coated multielectrode array (MEA) dishes at D14 of 
differentiation. The cells were regularly measured on the Axion Maestro Pro MEA 
device. Cells attached to the multielectrode plate and showed functional activity 
already at D20 of differentiation starting from the hiPSC stage (Figure 34A and B). The 
mean firing rate at D20 was at approximately 0.01Hz and increasing up to 0.95Hz at 
D32. Afterwards, mean firing rate seemed to decrease until 0.025Hz. Same trend could 
be observed for the number of active electrodes, burst frequency and burst duration. 
Bursting of cells started between D20 and D26 of differentiation. 
The high variability of the measurements could be attributed to the fact that coating of 
the plates could be optimized: On one hand coating might vary as the bottom of 
multielectrode plates is made of glass whereas the other plates used to culture cells 
were made of plastic, for which the coating protocol was initially optimized for. On 
multielectrode plates cells formed patches and neurites looked like connecting fibers, 
it is possible that they were not attached tightly to the well, which is highly needed for 
proper recording of signals by the electrodes, which are incorporated in the plate 
 
Figure 64: Multielectrode analysis indicates functional activity of neurons. 
hiPSC_1 was differentiated into neurons. At D14 of differentiation, cells were replated on a multielectrode plate. 
A: Phase contrast analysis of neurons plated on multielectrode plate.  
B: Activity measurements of neurons. Cells were already functionally active at D20 and activity is increasing 
over time. Bursting starts between D20 and D26 of differentiation. Error bars: SEM. 
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bottom (Figure 34B). Therefore, cells might detach after a certain amount of time, 
indicating the decrease of activity after D32 of differentiation, but not necessarily a 
decrease in neural activity (Figure 34). 
In general, the cells were already active from D20 of differentiation with a trend of 
growing mean firing rate over time, which could be optimized using better attachment 
conditions. 
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3.2.10 Aβ phenotype can be recapitulated in vitro by the use of the established 
differentiation protocol 
The next question was: Is the differentiation protocol suitable for deriving neurons 
capable of modeling disease-relevant features in AD? 
For the following experiment, a healthy control line hiPSC_4, and the AD line PSEN1 
were differentiated into neurons with the aforementioned protocol. Already from D15 
onwards, morphologically mature neurons were visible (Figure 35A). Medium 
supernatants were collected at D20 and D45 of differentiation to perform Aβ ELISA 
using the MSD ELISA platform. 
The ratio of Aβ42/40 was calculated for the two time points and a significant difference 
was seen between hiPSC_4 and the PSEN1 line for each of the time points 
(Figure 35B). The Aβ42/40 was approximately three-fold higher for the PSEN1-
diseased line compared to the healthy control line hiPSC_4, which is expected from a 
mutation that is known to shift the ratio of 42/40 to a higher value, thus causing AD 
 
Figure 66: Aβ phenotype can be recapitulated in the established cell culture system. hiPSC_4 and 
hiPSC_PSEN1 were differentiated into neurons. 
A: Phase contrast images of neurons at D15, D20 and D45 of differentiation. Cells form denser structures over 
time of differentiation. Scale bar: 50µm. 
B: Supernatant of hiPSC-derived neurons from hiPSC_4 and hiPSC_PSEN1 were collected at D20 and 45 and 
an Aβ MSD-ELISA was performed. Samples were measured in technical triplicates. Data was processed in the 
ratio of Aβ42/40. As all samples per time point were normally distributed, an unpaired t-test was performed to 
compare the cell lines with each other at a certain time point. When comparing one cell line on both time points, 
either an unpaired t-test was performed or a Welch’s t-test in case of different variances. The hiPSC_PSEN1 
shows approximately three times higher Aβ42/40 ratios than the control line hiPSC_4. The measurements were 
performed in three technical replicates. P=0.0006 for hiPSC_4 and PSEN1 at D20, p<0.0001 for D45. Error 
bars: SD. 
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(Kondo et al., 2013). Further, the ratio did not show any difference between day 20 and 
45 when considered each line alone (Figure 35B). However, standard deviation was 
greater at day 20 compared to day 50 for both cell lines. An explanation might be, that 
cells are more variable when they are younger compared to an older time point when 
they have matured and equalized for a longer time. 
The findings indicated that the Aβ42/40 ratio did not change much over time in a cell 
line and therefore, disease modeling for the Aβ phenotype was already possible at 
early differentiation stages, and also indicating that the protocol can be used to model 
key AD pathology in vitro. 
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4 DISCUSSION 
In this work an hiPSC-derived neuronal cell culture system was established which is 
xeno-free, chemically defined, quick and robust. Understanding of the biology 
underlaying the different behavior of different hiPSC lines was crucial for optimization 
of the protocol. It was shown that it bears the potential for studying cortical diseases, 
such as Alzheimer’s Disease and other tauopathies. 
4.1 Implementation of xeno-free and chemically-defined cell culture conditions 
An ethical concern in research and development is the use of animals or animal-
derived components, such as sera and serum-derived proteins. In the context of the 
“3R-concept”, the use of animals should be reduced, replaced and refined (Russel and 
Burch, 1992). In this context, a goal was to develop a cell culture system that is xeno-
free, which means free of ingredients of foreign species. Thus, when working with 
hiPSCs, the components in the media should derive from human or from recombinant 
proteins manufactured in an animal-free manner. Here, chemically-defined media were 
used with recombinant human proteins that were manufactured in an animal-free 
procedure. Supplements which contained animal proteins, for instance the B27 
supplement needed for differentiation, was switched to a xeno-free version. 
Further, instead of using Matrigel as a coating agent for hiPSCs, NPCs and neurons, 
two different coating agents were assessed, namely human recombinant vitronectin 
(VTN-N) and laminin-521 (LN521). VTN-N is widely used as coating agent in 
combination with the E8flex medium. Nevertheless, advantages were found when 
using LN521: It seems to be component in the extracellular matrix of an embryo as 
well as in the cortex (Hyysalo et al., 2017; Laperle et al., 2015). Therefore, this coating 
appeared attractive as it can be used throughout the differentiation process without 
switching to another matrix protein. An additional advantage of replacing Matrigel by 
LN521 is that the variability in cell culture can also be reduced as Matrigel might contain 
various growth factors as contaminants that might affect culture, which is not the case 
for recombinant proteins. LN521 was already tested in hiPSCs with beneficial effects: 
Cells adhere, grow and maintain their pluripotency (Laperle et al., 2015; Rodin et al., 
2014). 
When switching hiPSCs from Matrigel to LN521, a higher attachment rate of hiPSCs 
compared to Matrigel was observed. This has the advantage of not losing that many 
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cells during the passaging process. Additionally, the maintenance of hiPSCs on LN521 
showed a persistent OCT4 expression of the cells, indicating the maintenance of their 
pluripotency state, as expected from their growth pattern. 
Nevertheless, other animal-derived ingredients had to be switched to recombinant 
solutions: This was the case for BSA towards HSA. As BSA is one ingredient of the 
B27 supplement, the need to switch to its xeno-free counterpart, mainly CTS-B27, was 
mandatory. Cell morphology and differentiation ability were unaffected by all aspects 
observed and measured. 
The CTS-B27 belongs to a product line that is cell therapy competent: That means that 
the established cell culture system is a step closer to be of quality of cell replacement 
therapies. But to achieve this high-quality standard, other ingredients also need to be 
certified in that direction. This is not the case as in this work, the main focus was to 
develop a chemically-defined and above all a xeno-free system for research use. 
Further, the costs of ingredients rise with higher quality standards, which makes the 
system less affordable for use in research only. This has to be taken into consideration, 
but the steps towards cell replacement quality seem feasible. 
A last step into the direction of a chemically defined and xeno-free culture system was 
the exchange of the proteins FGF, BDNF and GDNF towards recombinant proteins 
manufactured in an animal-free manner as well as replacing the carrier protein, that 
again is BSA, into HSA. This also has to be applied during the process of reconstitution 
of the recombinant proteins and generating working stock solutions. When using these 
xeno-free proteins, functional cortical neurons could be derived out of the protocol. 
All in all, it can be concluded that the switch towards xeno-free and chemically-defined 
ingredients in the cell culture system worked well as the goal of differentiation, meaning 
guiding hiPSCs towards cortical neurons, was achieved. 
 
4.2 Development of a robust differentiation protocol to generate hiPSC-derived 
cortical neurons 
In the course of establishing an hiPSC-derived neuronal cell culture system, the goal 
was to define a differentiation protocol that is very robust and applicable on a lot of 
different hiPSC lines, ideally all hiPSC lines tested. 
Several factors might influence variability in culture and therefore, the robustness of a 
protocol: One factor already addressed is the use of animal-derived ingredients which 
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might vary from batch to batch due to being natural compounds or components. By 
developing a more chemically-defined protocol, this factor could already be minimized. 
As a next step, variability was eliminated by choosing an adherent cell culture system. 
The use of a 3D culture system might be indeed more physiological than an adherent 
2D culture system. But it bears several variability potentials: The forming 3D embryoid 
bodies vary greatly in size and therefore, the system is not very scalable and 
reproducible. Further, when applying for instance small molecules and other pathway 
modulators such as growth factors, penetration into the embryoid body might be 
hindered, especially for growth factors that are larger than small molecules. Further, a 
gradient of small molecules and growth factors will form from the outside of the 
embryoid body to the inside, differently affecting differentiation of the cells in the 
embryoid body (Van Winkle et al., 2012). 
Further, it is impossible to derive only a single cell type when using a 3D approach: 
Other cell types will arise that will “contaminate” the wanted cell type and a cell 
segregation step might be necessary (Lancaster and Knoblich, 2014). Therefore, it is 
much easier to derive a single cell type when using an adherent cell culture. 
 
The robustness of a differentiation protocol further underlies the beneficial 
manipulation of pathways in the system. Such pathways in this regard were identified 
to be the WNT and BMP pathways.  
 
WNT signaling is an important factor to consider during differentiation: Endogenous 
WNT signaling activity might vary among lines and also can change dynamically over 
time (Blauwkamp et al., 2012; Moya et al., 2014; Ortmann and Vallier, 2017). This in 
turn might affect differentiation capabilities of cells. This was also observed, when 
differentiating the cells without WNT inhibitor: hiPSC_1 showed neural crest formation, 
which could be prevented when the general WNT inhibitor IWP2 was applied. In that 
regard the aim was to clarify the effect of WNT signaling in our cell culture system. We 
found out that endogenous non-canonical WNT signaling might lead to unwanted 
neural crest differentiation. When applying the canonical WNT inhibitor XAV939 (XAV), 
sphere formation and therefore neural crest cannot be prevented, contradictory to 
findings of Qi and colleagues (Qi et al., 2017) 
In their differentiation condition they use the canonical WNT inhibitor XAV to reduce 
neural crest formation, whereas in our cell culture system this inhibition is not enough 
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to prevent neural crest formation. Instead, when they use CHIR99021, which activates 
canonical WNT signaling, their cells express the neural crest marker SOX10 (Qi et al., 
2017). A possible explanation to the contradictory findings might be that Qi and 
colleagues use dSMADi as main induction condition, whereas in this protocol here only 
BMP and MEK inhibitors are applied for induction. Also, it cannot be ruled out that if 
less WNT signaling-prone lines are used, XAV as a WNT inhibitor is sufficient to 
prevent neural crest formation. Therefore, the difference might underly the different 
induction paradigms. Pathway crosstalk cannot be completely excluded, but for the 
presented differentiation paradigm, complete block of endogenous WNT signaling, 
independent of canonical or non-canonical, by the use of IWP2 is recommended and 
worked in even difficult to differentiate hiPSC lines. 
 
Another factor contributing to variability in cell culture during neural induction was found 
to be BMP signaling: It became clear that in case BMP signaling is inefficiently blocked 
in the culture, the risk of non-neural ectoderm formation appears (Tchieu et al., 2017; 
Wilson and Hemmati-Brivanlou, 1995). In this regard we found out that the BMP 
inhibitor LDN 193189 (LDN) better inhibits BMP signaling than Dorsomorphin (DM): 
LDN is a second generation BMP inhibitor and therefore, its efficacy is expected to be 
better than the one of DM. Many protocols use DM to block BMP signaling in the 
dSMADi paradigm, without reporting too much formation of non–neural ectoderm. The 
most likely explanation why complete BMP inhibition was crucial in the protocol which 
was developed here is that additionally, blockage of FGF signaling was used. As 
discussed above, this was greatly accelerating differentiation, but if FGF is blocked 
and BMP signaling is present, ectodermally determined cells efficiently form non-
neural ectoderm (Tchieu et al., 2017). This allowed the identification of LDN as the 
superior BMP inhibitor for this and future applications in differentiating hiPSCs. 
Further, density-dependent effects on differentiation were found: Contrary to findings 
of Chambers and colleagues, it was found out that neural crest formation is reciprocally 
proportional to initial cell density during induction (Chambers et al., 2009). Further, a 
density dependence was found towards non-neural ectoderm formation. Here again, 
the contradictory differences might be attributed to the different differentiation 
paradigms used: Chambers uses dSMADi, contrary to the work here, in which 
inhibitors of BMP, MEK and WNT were used. Still, in the end, the developed 
differentiation protocol here can be applied efficiently to hiPSCs to derive cortical 
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neurons. Further, several factors were identified that might affect robustness of the 
differentiation, such as BMP and WNT signaling, that was examined here in more 
detail. We found out differences between canonical and non-canonical WNT signaling 
and that non-canonical WNT signaling contributes to neural crest formation, when 
canonical signaling is inhibited. 
Also, other signaling pathways can be influenced in the established differentiation 
protocol: SHH was described as a signaling pathway that is important in patterning of 
the ventral region of the neural tube. In case a GABAergic culture is derived out of the 
differentiation protocol, a way to dorsalize the culture might be the inhibition of SHH by 
Cyclopamine (Cao et al., 2017; Li et al., 2009). Application of Cyclopamine during 
neural induction in this cell culture setting does not influence neuroectoderm formation 
in a negative way. Further, Cyclopamine could also be applied during expansion of 
NPCs to avoid ventral cultures to manifest. 
 
All these findings indicate that it is important to know the cells in use and their pathway 
activity: The more is known about the pathways and their degree of activity, the better 
can the pathways be identified that need modulation to derive the cell type of interest. 
A universally applicable differentiation protocol should therefore take all possible 
pathway deviations into account and block/activate these as needed. That would allow 
the highest number of lines to be differentiated, independently of whether each 
pathway inhibitor is needed for each individual line to the same extend. It should be 
further noted that the strategy to specifically focus on hard-to-differentiate hiPSC lines, 
such as hiPSC_1, turned out to be crucial for successfully developing such a robust 
differentiation system. 
4.3 Establishment of a quick differentiation protocol from hiPSC towards cortical 
neurons 
Differentiation protocols from hPSCs towards cortical neurons already existed (Kirwan 
et al., 2015; Shi et al., 2012a). A big challenge is to accelerate the differentiation so 
that the length of usually several months could be reduced to only several weeks. Here, 
an alternative towards cortical neuron differentiation was presented: A different 
paradigm was used to the generally applied dSMADi, which inhibits BMP and TGF-β 
pathways to derive neuroectodermal cells. It was found out that inhibition of TGF-β 
pathways is not necessary for neural induction. By the help of MEK inhibition the 
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induction phase could be accelerated so that only 6 days of induction are need instead 
of 12 days (Kirwan et al., 2015; Shi et al., 2012a). 
 
The established cell culture system has a freezable neural progenitor cell (NPC) type. 
By this advantage larger batches of NPCs can be generated and in later stages, 
10 days of induction and expansion can be saved. Also, it has to be taken into 
consideration that in routine application of the protocol, time saving is even higher, as 
the need for taking or keeping hiPSC lines in culture prior to neural induction is also 
non-existent if frozen batches of NPCs are used. The frozen batches also allow 
generation of large stocks, which can be used for repetitive experiments more robustly, 
as also hiPSC lines from different passages are not induced each time. Further, 
neurons can be derived from D15 of differentiation on, which are already showing 
electrophysiological activity from D20 of differentiation. This is comparable to a recent 
publication by Qi et al: They describe in their differentiation protocol that their neurons 
are functionally active from D16 onwards of differentiation (Qi et al., 2017). On the 
other hand, they lack a freezable progenitor.  
 
4.4 Alzheimer’s Disease modeling with hiPSC-derived neurons 
When using the differentiation protocol with an Alzheimer patient-derived hiPSC line, 
namely hiPSC_PSEN1, the Aβ phenotype typical for AD could be recapitulated in vitro, 
proving, that the developed protocol and thus the developed cell culture system is 
suitable for AD modeling. Further, the disease phenotype could already be identified 
within 20 days of differentiation compared to already published Aβ disease modeling 
from Kondo and colleagues, which performed Aβ phenotyping at D72 of differentiation 
(Kondo et al., 2013). 
For a more physiological disease modeling approach or to check how other cell types 
are involved in the AD phenotype a co-culture system of neurons with, for instance 
astrocytes, microglia or all three of them would be an option (Oksanen et al., 2017; 
Sirkis et al., 2016). Still, it should be noted that this would make cultures more complex 
and individual cellular contributions more difficult to elaborate. 
The differentiation protocol makes our developed cell culture system very suitable for 
Aβ disease modeling already at an early differentiation stage, which is a key feature of 
AD pathology. 
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4.5 General conclusion 
It can be concluded that the established differentiation protocol from hiPSCs towards 
cortical neurons is successful with regards to several aspects: 
The culturing environment of hiPSCs as well as the differentiation protocol itself were 
established in a xeno-free manner which makes it consistent with the “3R-concept” 
which aims to replace, refine and reduce the use of animals and animal-derived 
components in research (Russel and Burch, 1992). 
An advantage of the established differentiation protocol is the accelerated induction 
phase leading to a greatly accelerated differentiation: By the use of the MEK inhibitor 
PD0325901, the induction phase of the protocol could be reduced by 50% compared 
to other differentiation protocols (Kirwan et al., 2015; Shi et al., 2012a). 
An additional advantage of this protocol is that a neural progenitor is generated which 
is suitable for freezing: The progenitor that is formed after the induction and expansion 
phase can be frozen down in large batches and thawed for final maturation.  
Further, the differentiation protocol can be used for all hiPSC lines so far tested and 
also for lines that seem to be more prone for neural crest formation: By the use of the 
WNT inhibitor IWP2 present during neural induction as well as during expansion the 
established differentiation protocol prevents the formation of neural crest in culture.  
In case hiPSC lines need to be used with this differentiation protocol in the future that 
do not behave like all the lines tested, other signaling pathways can be modulated at 
any time, such as it was tested for SHH signaling by adding the SHH inhibitor 
Cyclopamine (Cao et al., 2017). This makes the differentiation protocol adjustable to 
any hiPSC line if needed, although it was not observed that this treatment was 
necessary or had any additional beneficial effect in all lines tested so far. This could 
be an intrinsic feature of the paradigm used, or just no SHH signaling present in these 
cell lines. Observation of SHH expression in the cells in future experiments could be 
used to mitigate that risk and act accordingly, if needed. 
Further, the hiPSC-derived neurons are positive for early layer cortical marker TBR1 
and for several structural markers, such as MAP2, β3-tubulin and tau. The expression 
of the more early (lower cortical layer) marker TBR1 is also expected for a fast protocol, 
as it was shown that the formation of later (upper) cortical layers in vitro is recapitulating 
fetal development, where these layers are also formed later in CNS formation (Shi et 
al., 2012b). This derived neuronal culture is suitable for AD modeling: The Aβ 
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phenotype, which is a key pathology for modeling AD in vitro, was already detectable 
within 20 days of differentiation.  
With all these findings it was able to develop a quick and robust differentiation protocol 
towards cortical neurons which could be used in several healthy control hiPSC lines 
but also in diseased lines such as the AD hiPSC_PSEN1 line and the tauopathy 
hiPSC_MAPT line. 
Here, the minimal differentiation conditions were identified to derive cortical neurons 
without the risk of obtaining a foreign cell type, such as neural crest or non-neural 
ectoderm: Inhibition of BMP, MEK and WNT. In case other pathways influence the 
differentiation in a negative way, these might also be addressed. Figure 36 summarizes 
the signaling pathways that might lead to an unwanted cell type outcome (Figure 36).  
  
The established protocol bears a great potential with regards to study the molecular 
mechanisms of AD and some tauopathies, for target identification and drug discovery, 
but without the need for animal-derived components. 
 
Figure 68: Proposed differentiation strategies and influence of pathways on differentiation of hiPSCs. 
For neuroectoderm formation it is necessary to inhibit BMP pathway. Inhibition of general WNT signaling is 
crucial to avoid neural crest formation. Inhibition of SHH is not always necessary and only needed in case of 
high SHH expression in the cells. To finally mature cortical neurons from NPCs, inhibition of FGF and Notch 
signaling are beneficial. NEE: Non-neural ectoderm, Cyclo: Cyclopamine, NC: neural crest, NPCs: neural 
progenitor cells. 
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5 SUMMARY 
In an aging world, neurodegenerative diseases, such as Alzheimer’s Diseases start to 
appear more and more in society. Unfortunately, only drugs ameliorating the 
symptoms, but no preventive or curative medications are available. One underlying 
reason is that only animal models exist that do not fully reflect the human 
pathophysiology, leading to the difficulty of translating findings into humans. Therefore, 
it is of great importance to access an authentic in vitro cell culture system to study 
disease. Such a cell culture system would also have the potential to be used in later 
stages of drug discovery and drug development. 
Here, a quick, robust and chemically-defined xeno-free differentiation protocol was 
developed to obtain a human induced pluripotent stem cell (hiPSC)-derived cortical 
neuron cell culture system. Several factors influencing variability of differentiation were 
addressed and identified, leading to faster generation of cells, greater robustness and 
wide applicability among different hiPSC lines. Further, it was shown that the derived 
culture system is suitable for disease modeling in Alzheimer’s Disease as the Aβ-
pathology could be recapitulated in the cells, already at a very early time point of 
differentiation.  
The established differentiation protocol is a promising tool in disease modeling of 
Alzheimer’s Disease and other tauopathies, without the need of animal-derived cell 
culture supplements and reagents. 
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6 ZUSAMMENFASSUNG 
Wir leben in einer immer älter werdenden Gesellschaft. In einer solchen Welt kommen 
neurodegenerative Erkrankungen, wie die Alzheimer-Erkrankung, immer öfter vor. 
Leider gibt es keine Medikamente, welche die Krankheit aufhalten, oder die Ursachen 
ursächlich bekämpfen. Lediglich welche, die die Symptome dämpfen. Ein Grund 
hierfür ist, dass nur Tiermodelle existieren, die die menschliche Pathophysiologie nicht 
komplett wiederspiegeln. Dies führt zu einer erschwerten Übertragung von 
Erkenntnissen auf den Menschen. Daher ist es von großer Wichtigkeit, ein 
authentisches in vitro Zellkultursystem zu erschaffen, um die Erkrankung zu 
untersuchen. Solch ein Zellkultursystem hätte auch das Potential in späteren Phasen, 
wie der Wirkstoffentdeckung und Medikamentenentwicklung, genutzt zu werden. 
In dieser Arbeit wurde ein schnelles, robustes und chemisch definiertes 
Differenzierungsprotokoll entwickelt, um ein von humanen, induzierten, pluripotenten 
Stammzellen (hiPSC) abgeleitetes kortikales Zellkultursystem für Nervenzellen zu 
erhalten. Zahlreiche Faktoren, die die Variabilität der Differenzierung betreffen, wurden 
untersucht und identifiziert, was zu einer schnelleren Generierung der Zellen, größerer 
Robustheit und Anwendbarkeit des Protokolls unter hiPSC-Linien führte. Des Weiteren 
wurde gezeigt, dass sich das abgeleitete Zellkultursystem als Krankheitsmodell für die 
Alzheimer-Erkrankung eignet, da die Aβ-Pathologie mit den Zellen nachgestellt 
werden konnte, und zwar bereits zu einem frühen Zeitpunkt der Differenzierung. 
Das etablierte Differenzierungsprotokoll ist ein vielversprechendes Werkzeug zur 
Modellierung der Alzheimer-Erkrankung und anderen Tauopathien, ohne den Bedarf 
von tierischen Zellkulturzusätzen oder von Tieren abstammenden Reagenzien. 
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